



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

03 March 2021
EMA/HMPC/45511/2017
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Hypericum perforatum* L., herba

2nd Draft – Revision 1

The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Abdali K, Khajehei M, Tabatabaee HR. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. *Menopause* 2010, 17(2):326-331

Aghili T, Arshami J, Tahmasbi AM, Haghparast AR. Effects of Hypericum perforatum extract on IgG titer, leukocytes subset and spleen index in rats. *Avicenna J Phytomed* 2014, 4(6):413-419

Agollo MC, Miszputen SJ, Diament J. Hypericum perforatum-induced hepatotoxicity with possible association with copaiba (*Copaifera langsdorffii* Desf): case report. *Einstein (Sao Paulo)* 2014, 12(3):355-357

Agostinis P, Vantieghem A, Merlevede W, de Witte PAM. Hypericin in cancer treatment: more light on the way. *Int J Biochem Cell Biol* 2002, 34:221-241

Agrosi M, Mischiatti S, Harrasser PC, Savio D. Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology. *Phytomedicine* 2000, 7:455-462

Al-Akoum M, Maunsell E, Verreault R, Provencher L, Otis H, Dodin S. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. *Menopause* 2009, 16(2):307-314

Alscher DM, Klotz U. Drug interaction of herbal tea containing St. John's wort with cyclosporine. *Transpl Int* 2003, 16:543-544

Amini Z, Boyd B, Doucet J, Ribnicki DM, Stephens JM. St. John's Wort inhibits adipocyte differentiation and induces insulin resistance in adipocytes. *Biochem Biophys Res Commun* 2009, 388(1):146-149

Andelic S. Bigeminy – a result of digoxin and St. John's wort interaction. *Vojnosanit Pregl* 2003, 60:361-364



- Andren L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. *Eur J Clin Pharmacol* 2007, 63: 913-916
- Angheliescu IG, Kohnen R, Szegedi A, Klement S, Kieser M. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. *Pharmacopsychiatry* 2006, 39:213-219
- Anyzewska M, Kowalczyk A, Łozak A, Jabłczyńska R, Fijałek Z. Determination of total hypericins in St. John's wort and herbal medicinal products. *Acta Pol Pharm* 2010, 67(6):586-592
- Arndt S, Haag SF, Kleemann A, Lademann J, Meinke MC. Radical protection in the visible and infrared by a hyperforin-rich cream—*in vivo* versus *ex vivo* methods. *Exp Dermatol* 2013, 22(5):354-357
- Arokiyaraj S, Balamurugan R, Augustian P. Antihyperglycemic effect of Hypericum perforatum ethyl acetate extract on streptozotocin-induced diabetic rats. *Asian Pac J Trop Biomed* 2011, 1(5):386-390
- Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, *et al.* No relevant interaction with alprazolam, caffeine, tolbutamide and digoxin by treatment with a low-hyperforin St John's wort extract. *Planta Med* 2005, 71:331-337
- Arsić I, Zugić A, Tadić V, Tasić-Kostov M, Mišić D, Primorac M, *et al.* Estimation of dermatological application of creams with St. John's Wort oil extracts. *Molecules* 2012, 17(1):275-294
- Asgary S, Solhpour A, Parkhideh S, Madani H, Mahzouni P, Kabiri N. Effect of hydroalcoholic extract of Hypericum perforatum on selected traditional and novel biochemical factors of cardiovascular diseases and atherosclerotic lesions in hypercholesterolemic rabbits: A comparison between the extract and lovastatin. *J Pharm Bioallied Sci* 2012, 4(3):212-218
- Auster F, Schäfer J. *Arzneipflanzen*. Georg Thieme Verlag, Leipzig 1958
- Axarlis S, Mentis A, Demetzos C, Skaltsounis AL, Marselos M, Malamas M. Antiviral *in vitro* activity of Hypericum perforatum extract on the Human Cytomegalovirus (HCMV). *Phytother Res* 1998, 12:507-511
- Barbenel DM, Yusufi B, O'Shea D, Bench CJ. Mania in a patient receiving testosterone replacement post-orchidectomy taking St John's wort and sertraline. *J Psychopharmacol* 2000, 14(1): 84-86
- Barnes J, Anderson LA, Phillipson JD. *Herbal medicines*. 2nd ed. Pharmaceutical Press, London 2002
- Barnes J, Barber N, Wheatley D, Williamson EM. A pilot randomised, open, uncontrolled, clinical study of two dosages of St John's wort (Hypericum perforatum) herb extract (LI-160) as an aid to motivational/behavioural support in smoking cessation. *Planta Med* 2006, 72:378-382
- Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. *Transplantation* 2001, 71:239-241
- Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. *Ann Pharmacother* 2000, 34:1013-1016
- Bauer S, Störmer E, Johne A, Krüger H, Budde K, Neumayer HH, *et al.* Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. *Br J Clin Pharmacol* 2003, 55:203-211
- Bauer S, Störmer E, Kerb R, Johne A, Brockmöller J, Roots I. Differential effects of Saint John's wort (Hypericum perforatum) on the urinary excretion of D-glucaric acid and 6 β -hydroxycortisol in healthy volunteers. *Eur J Clin Pharmacol* 2002, 58:581-585

- Baureithel KK, Berger Büter K, Engesser A, Burkard W, Schaffner W. Inhibition of benzodiazepine binding *in vitro* by amentoflavone, a constituent of various species of *Hypericum*. *Pharm Acta Helv* 1997, 72:153-157
- Bayramoglu G, Bayramoglu A, Engur S, Senturk H, Ozturk N, Colak S. The hepatoprotective effects of *Hypericum perforatum* L. on hepatic ischemia/reperfusion injury in rats. *Cytotechnol* 2014, 66:443-448
- Beattie PE, Dawe RS, Traynor NJ, Woods JA, Ferguson J, Ibbotson SH. Can St John's wort (hypericin) ingestion enhance the erythematous response during high-dose ultraviolet A1 therapy? *Br J Dermatol* 2005, 153:1187-1191
- Beer AM, Ostermann T. Cyclosporine interaction with St. John's wort (*Hypericum perforatum*) increases the risk of graft rejection and causes a raise of the daily medication costs. *Med Klin* 2001, 96:480-484
- Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. *Hypericum perforatum* versus fluoxetine in the treatment of mild to moderate depression. *Adv Ther* 2002, 19:43-52
- Bejjamini V, Andreatini R. Effects of *Hypericum perforatum* and paroxetine on rat performance in the elevated T-maze. *Pharmacol Res* 2003, 48:199-207
- Bell EC, Ravis WR, Braxton Lloyd K, Stokes TJ. Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. *Ann Pharmacother* 2007a, 41:229-234
- Bell EC, Ravis WR, Chan HM, Lin YJ. Lack of pharmacokinetic interaction between St. John's wort and prednisone. *Ann Pharmacother* 2007b, 41:1819-1824
- Benedi J, Arroyo R, Romero C, Martin-Aragon S, Villar AM. Antioxidant properties and protective effects of a standardized extract of *Hypericum perforatum* on hydrogen peroxide-induced oxidative damage in PC12 cells. *Life Sci* 2004, 75:1263-1276
- Bergmann R, Nüßner J, Demling J. Behandlung leichter bis mittelschwerer Depressionen. *TW Neurol Psychiatr* 1993, 7:235-240
- Bernd A, Simon S, Ramirez Bosca A, Kippenberger S, Diaz Alperi J, Miquel J, et al. Phototoxic effects of *Hypericum* extract in cultures of human keratinocytes compared with those of psoralen. *Photochem Photobiol* 1999, 69:218-221
- Bertoli A, Cirak C, Leonardi M, Seyis F, Pistelli L. Morphogenetic changes in essential oil composition of *Hypericum perforatum* during the course of ontogenesis. *Pharm Biol* 2011, 49(7):741-751
- Bhattacharya SK, Chakrabarti A, Chatterjee SS. Activity profiles of two hyperforin-containing *Hypericum* extracts in behavioral models. *Pharmacopsychiatry* 1998, 31(Suppl.):22-29
- Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of hyperforin from *Hypericum* extracts in rats and human volunteers. *Pharmacopsychiatry* 1998, 31, Suppl. 1:36-43
- Billard C, Merhi F, Bauvois B. Mechanistic insights into the antileukemic activity of hyperforin. *Curr Cancer Drug Targets* 2013, 13(1):1-10
- Bjerkensted L, Edman GV, Alken RG, Mannel M. *Hypericum* extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. *Eur Arch Psychiatry Clin Neurosci* 2005, 255:40-47
- Böhme H. Kommentar zum Europäischen Arzneibuch. Wissenschaftliche Verlagsgesellschaft, Stuttgart 2006
- Boiy A, Roelandts R, van den Oord J, de Witte PA. Photosensitizing activity of hypericin and hypericin acetate after topical application on normal mouse skin. *Br J Dermatol* 2008, 158(2):360-369

- Bolley R, Zulke C, Kammerl M, Fischereeder M, Kramer BK. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. *Transplantation* 2002, 73:1009
- Bonetto N, Santelli L, Battistin L, Cagnin A. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and Hypericum. *Cephalagia* 2007, 27:1421-1423
- Booth JN 3rd, McGwin G. The association between self-reported cataracts and St. John's Wort. *Curr Eye Res* 2009, 34(10):863-866
- Borges LV, do Carmo Cancino JC, Peters VM, Las Casas L, de Oliveira Guerra M. Development of pregnancy in rats treated with Hypericum perforatum. *Phytother Res* 2005, 19:885-887
- Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. *AAPS J* 2009, 11(4):710-727
- Böttcher M, Mück W, Ochmann K, Rohde G, Unger S, Hindmarch I. Investigation of the safety, tolerability, pharmacodynamics and pharmacokinetics of Remotiv (Hypericum extract Ze 117). *Eur J Clin Pharmacol* 2000, 56:A10
- Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John's wort. *Lancet* 1998, 352:1121
- Bracher A. Johanniskraut 1 x täglich: Wirkung klinisch belegt. *Ärztliche Praxis extra* 2001,51
- Bradley P. British Herbal Compendium. Vol 2. British Herbal Medicine Association 2006
- Brattström A. Long-term effects of St. John's wort (Hypericum perforatum) treatment: a 1-year safety study in mild to moderate depression. *Phytomed* 2009, 16:277-283
- Bray BJ, Perry NB, Menkes DB, Rosengren RJ. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. *Toxicol Sci* 2002, 66:27-33
- Bray BJ, Brennan NJ, Perry NB, Menkes DB, Rosengren RJ. Short term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse. *Life Sci* 2002, 70:1325-1335
- Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John's wort with ciclosporin. *Lancet* 2000a, 355:1912
- Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). *Transplantation* 2000b, 69:2229-2230
- Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M, et al. St. John's wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. *Brain Pathol* 2014, 24:18-24
- Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. *Clin Ther* 2000, 22:411-419
- Breyer A, Elstner M, Gillesen T, Weiser D, Elstner E. Glutamate-induced cell death in neuronal HT22 cells is attenuated by extracts from St. John's wort (*Hypericum perforatum* L.). *Phytomed* 2007, 14:250-255
- Brockmüller J, Reum S, Bauer S, Kerb R, Hübner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. *Pharmacopsychiat* 1997(Suppl.), 30:94-101

- Buchholzer ML, Dvorak C, Chatterjee SS, Klein J. Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort. *J Pharmacol Exper Ther* 2002, 30:714-719
- Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John's wort on carbamazepine pharmacokinetics in healthy volunteers. *Clin Pharmacol Ther* 2000, 68:605-612
- Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from *Hypericum perforatum* exert antidepressant activity in the forced swimming test. *Planta Med* 1998, 64:291-294
- Butterweck V, Jurgenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from *Hypericum perforatum* show antidepressant activity in the forced swimming test. *Planta Med* 2000, 66:3-6
- Butterweck V, Böckers T, Korte B, Wittkowski W, Winterhoff H. Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. *Brain Res* 2002a, 930:21-29
- Butterweck V, Lieflander-Wulf U, Winterhoff H, Nahrstedt A. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. *Planta Med* 2003, 69:189-192
- Butterweck V, Nahrstedt A, Evans J, Hufeisen S, Rauser L, Savage J, et al. *In vitro* receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. *Psychopharmacol* 2002b, 162:193-202
- Butterweck V, Nahrstedt A. Was ist bekannt über Johanniskraut? Phytochemie und Pharmakologie. *Pharmazie in unserer Zeit* 2003, 32:212-219
- Butterweck V, Nahrstedt A, Evans J, Hufeisen S, Rauser L, Savage J, et al. *In vitro* receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. *Psychopharmacol* 2002, 162:193-202
- Butterweck V, Wall A, Liefänder-Wulf U, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of *Hypericum perforatum* in animal assays for antidepressant activity. *Pharmacopsychiatry* 1997, 30(Suppl.):117-124
- Cabrelle A, Dell'Aica I, Melchiori L, Carraro S, Brunetta E, Niero R, et al. Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease. *J Leukoc Biol* 2008, 83(1):212-219
- Caccia S, Gobbi M. St. John's wort components and the brain: uptake, concentrations reached and the mechanisms underlying pharmacological effects. *Curr Drug Metab* 2009, 10(9):1055-1065
- Cada AM, Hansen DK, Laborde JB, Ferguson SA. Minimal effects from developmental exposure to St. John's wort (*Hypericum perforatum*) in Sprague-Dawley rats. *Nutr Neurosci* 2001, 4:135-141
- Caelo 2008: personal communication
- Calapai G, Crupi A, Firenzuoli F, Costantino G, Inferrera G, Campo GM, et al. Effects of *Hypericum perforatum* on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. *J Pharm Pharmacol* 1999, 51:723-728
- Calapai G, Crupi A, Firenzuoli F, Interrera G, Squadrito F, Parisi A, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of *Hypericum perforatum*. *Pharmacopsychiatry* 2001, 34:45-49

- Camfield DA, Scholey AB, Pipingas A, Silberstein RB, Kure C, Zangara A, *et al.* The neurocognitive effects of *Hypericum perforatum* Special Extract (Ze 117) during smoking cessation. *Phytother Res* 2013, 27(11):1605-1613
- Campos LV, Vieira VA, Silva LR, Jasmin J, Guerra MO, Peters VM, *et al.* Rats treated with *Hypericum perforatum* during pregnancy generate offspring with behavioural changes in adulthood. *Rev Bras Farmacogn* 2017, 27:361-368
- Can OD, Öztürk Y, Ozkay DU. Effects of insulin and St. John's Wort treatments on anxiety, locomotory activity, depression, and active learning parameters of streptozotocin-diabetic rats. *Planta Med* 2011a, 77(18):1970-1976
- Can ÖD, Öztürk Y, Öztürk N, Sagratini G, Ricciutelli M, Vittori S, *et al.* Effects of treatment with St. John's Wort on blood glucose levels and pain perceptions of streptozotocin-diabetic rats. *Fitoterapia* 2011b, 82(4):576-584
- Canning S, Waterman M, Orsi N, Ayres J, Simpson N, Dye L. The efficacy of *Hypericum perforatum* (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. *CNS Drugs* 2010, 24(3):207-225
- Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S. Hyperforin contributes to the hepatic CYP3A-inducing effect of *Hypericum perforatum* extract in the mouse. *Toxicol Sci* 2003, 75:25-30
- Capasso R, Borrelli F, Montanaro V, Altieri V, Capasso F, Izzo AA. Effects of the antidepressant St. John's wort (*Hypericum perforatum*) on rat and human vas deferens contractility. *J Urol* 2005, 173:2194-2197
- Capasso R, Borrelli F, Aviello G, Capasso F, Izzo AA. Inhibitory effect of the herbal antidepressant St. John's wort (*Hypericum perforatum*) on rat gastric motility. *Naunyn Schmiedebergs Arch Pharmacol* 2008, 376(6):407-414
- Carvalho LA, Gorenstein C, Moreno R, Pariante C, Markus RP. Effect of antidepressants on melatonin metabolite in depressed patients. *J Psychopharmacol* 2009, 23(3):315-321
- Catania MA, Firenzuoli F, Crupi A, Mannucci C, Caputi AP, Calapai G. *Hypericum perforatum* attenuates nicotine withdrawal signs in mice. *Psychopharmacol* 2003, 169:186-189
- Cayci MK, Dayioglu H. *Hypericum perforatum* extracts healed gastric lesions induced by hypothermic restraint stress in Wistar rats. *Saudi Med J* 2009, 30(6):750-754
- Cervo L, Roizo M, Ekalle-Soppo CB, Guiso G, Morazzoni P, Caccia S. Role of hyperforin in the antidepressant-like activity of *Hypericum perforatum* extracts. *Psychopharmacol* 2002, 164:423-428
- Chan LYS, Chiu PY, Lau TK. A study of hypericin-induced teratogenicity during organogenesis using a whole rat embryo culture model. *Fertility and Sterility* 2001, 76:1073-1074
- Chang Y, Wang SJ. Hypericin, the active component of St. John's wort, inhibits glutamate release in the rat cerebrocortical synaptosomes via a mitogen-activated protein kinase-dependent pathway. *Eur J Pharmacol* 2010, 634(1-3):53-61
- Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE. Hyperforin as a possible antidepressant component of *Hypericum* extracts. *Life Sci* 1998, 63:499-510
- Chaudhary A, Willett KL. Inhibition of human cytochrome CYP1 enzymes by flavonoids of St. John's wort. *Toxicol* 2006, 217: 194-205

- Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and Phenobarbital is mediated by the pregnane x receptor. *J Pharmacol Exp Therapeutics* 2004, 308:495-501
- Chung DJ, Kim HY, Park KH, Jeong KA, Lee SK, Lee YI, *et al.* Black Cohosh and St. John's Wort (GYNO-Plus(R)) for Climacteric Symptoms. *Yonsei Med J* 2007, 48:289-294
- Coleta M, Campas MG, Cotrim MD, Proenca da Cunha A. Comparative evaluation of *Melissa officinalis* L., *Tilia europaea* L., *Passiflora edulis* Sims. And *Hypericum perforatum* L. in the elevated plus maze anxiety test. *Pharmacopsychiatry* 2001, 34 S1:S20-21
- Coskun I, Tayfun Uzbay I, Ozturk N, Ozturk Y. Attenuation of ethanol withdrawal syndrome by extract of *Hypericum perforatum* in Wistar rats. *Fundam Clin Pharmacol* 2006, 20:481-488
- Cott JM. *In vitro* receptor binding and enzyme inhibition by *Hypericum perforatum* extract. *Pharmacopsychiatry* 1997, 30(Suppl.):108-112
- Crupi R, Abusamra YA, Spina E, Calapai G. Preclinical data supporting/refuting the use of *Hypericum perforatum* in the treatment of depression. *CNS Neurol Disord Drug Targets* 2013, 12(4):474-486
- Crupi R, Mazzon E, Marino A, La Spada G, Bramanti P, Battaglia F, *et al.* *Hypericum perforatum* treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. *BMC Complement Altern Med* 2011, 27;11:7
- Cui Y, Ang CYW, Beger RD, Heinze TM, Hu L, Leakey J. *In vitro* metabolism of hyperforin in rat liver microsomal systems. *Drug Metab Disposition* 2004, 32:28-34
- Czekalla J, Gastpar M, Hübner WD, Jäger D. The effect of *Hypericum* extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. *Pharmacopsychiatry* 1997, 30(Suppl.):86-88
- da Conceição AO, Takser L, Lafond J. Effect of St. John's Wort standardized extract and hypericin on *in vitro* placental calcium transport. *J Med Food* 2010, 13(4):934-942
- Dalmizrak O, Kulaksiz-Erkmen G, Ozer N. Evaluation of the *in vitro* inhibitory impact of hypericin on placental glutathione S-transferase pi. *Protein J* 2012, 31(7):544-549
- Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's wort. *J Psychopharmacol* 2002, 16:401
- Davidson JRT, Connor KM. St. John's wort in generalized anxiety disorder: three case reports. *J Clin Psychopharmacol* 2001, 21:635-636
- deMaat MMR, Hoetlmans RMW, Mathot RAA, vanGorp ECM, Meenhorst PL, Mulder JW, *et al.* Drug interactions between St. John's wort and nevirapine. *AIDS* 2001, 15:420-421
- De Marchis GM, Bürgl S, Kientsch U, Honegger UE. Vitamin E reduces antidepressant-related β -adrenoceptor down-regulation in cultured cells. Comparable effects of St. John's wort and tricyclic antidepressant treatment. *Planta Med* 2006, 72:1436-1437
- De Vry J, Maurel S, Schreiber R, de Beun R, Jentsch KR. Comparison of *Hypericum* extracts with imipramine and fluoxetine in animal models of depression and alcoholism. *Eur Neuropsychopharmacol* 1999, 9:461-468
- Demling JH, Müller J, Zeller K. Hoch dosierter Johanniskrautextrakt als tägliche Einmalgabe zur Behandlung von Depressionen. *Nervenheilkunde* 2004, 23:160-164

- Dikmen M, Oztürk Y, Sagratini G, Ricciutelli M, Vittori S, Maggi F. Evaluation of the wound healing potentials of two subspecies of *Hypericum perforatum* on cultured NIH3T3 fibroblasts. *Phytother Res* 2011, 25(2):208-214
- Dimpfel W. Electropharmacogram from quercetin is similar to that of moclobemide and other antidepressant drugs. *Z Phytother* 2008, 29:6
- Dinamarca MC, Cerpa W, Garrido J, Hancke JL, Inestrosa NC. Hyperforin prevents beta- amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid- beta- deposits. *Mol Psychiatry* 2006, 11:1032-1048
- Dost T, Ozkayran H, Gokalp F, Yenisey C, Birincioglu M. The effect of *Hypericum perforatum* (St. John's Wort) on experimental colitis in rat. *Dig Dis Sci* 2009, 54(6):1214-1221
- Dostalek M, Pistovcakova J, Jurica J, Sulcova A, Tomandl J. The effect of St John's wort (*hypericum perforatum*) on cytochrome p450 1a2 activity in perfused rat liver. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2011, 155(3):253-257
- Dostalek M, Pistovcakova J, Jurica J, Tomandl J, Linhart I, Sulcova A, et al. Effect of St John's wort (*Hypericum perforatum*) on cytochrome P-450 activity in perfused rat liver. *Life Sci* 2005, 78:239-244
- Dugoua JJ, Mill E, Perri D, Koren G. Safety and efficacy of St. John's wort (*Hypericum*) during pregnancy and lactation. *Can J Clin Pharmacol* 2006, 13:268-276
- Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. *Clin Pharmacol Ther* 2000, 68:598-604.
- Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. *Clin Pharmacol Ther* 2003, 73:41-50
- Eckert GP, Müller WE. Effects of hyperforin on the fluidity of brain membranes. *Pharmacopsychiatry* 2001, 34:22-25
- Eggertsen R, Andreasson A, Andren L. Effects of treatment with a commercially available St John's wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. *Scand J Prim Health Care* 2007, 25:154-159
- Eich-Höchli D, Oppliger R, Powell Golay K, Baumann P, Eap CB. Methadone maintenance treatment and St. John's wort – A case report. *Pharmacopsychiatry* 2003, 36:35-37
- El-Sherbiny DA, Khalifa AE, Attia AS, Eldenshary Eel D. *Hypericum perforatum* extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine. *Pharmacol Biochem Behav* 2003, 76:525-533
- Enning F, Murck H, Krieg JC, Vedder H. *Hypericum perforatum* differentially affects corticosteroid receptor-mRNA expression in human monocytic U-937 cells. *J Psychiatr Res* 2011, 45(9):1170-1177
- Ergänzungsbuch zum Deutschen Arzneibuch (Erg.-B6). Deutscher Apotheker-Verlag, Berlin 1941
- ESCOP Monograph. HYPERICI HERBA (St. John's Wort). ESCOP Monographs Second edition. ESCOP 2003
- Etemad L, Heidari MR, Heidari M, Moshiri M, Behravan E, Abbasifard M, et al. Investigation of *Hypericum perforatum* extract on convulsion induced by picrotoxin in mice. *Pak J Pharm Sci* 2011, 24(2):233-236

Etogo-Asse F, Boemer F, Sempoux C, Geubel A. Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and *Hypericum perforatum* (St. John's wort). Case of drug interaction? *Acta Gastroenterol Belg* 2008, 71(1):36-38

Evans RW. Triptans and serotonin syndrome. *Cephalgia* 2008, 28:573-575

Fahami F, Asali Z, Aslani A, Fathizadeh N. A comparative study on the effects of *Hypericum Perforatum* and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers. *Iran J Nurs Midwifery Res* 2010, 15(4):202-207

Fan L, Zhou G, Guo D, Liu YL, Chen WQ, Liu ZQ, et al. The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. *Clin Pharmacokinet* 2011, 50(9):605-611

Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. *J Clin Psychopharmacol* 2005, 25:441-447

Fegert JM, Kölch M, Zito JM, Glaeske G, Janhsen K. Antidepressant use in children and adolescents in Germany. *J Child Adolesc Psychopharmacol* 2006, 16:197-206

Feily A, Abbasi N. The inhibitory effect of *Hypericum perforatum* extract on morphine withdrawal syndrome in rat and comparison with clonidine. *Phytother Res* 2009, 23(11) :1549-1552

Feißt C, Pergola C, Rakonjac M, Rossi A, Koeberle A, Dodt G, et al. Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy *in vivo*. *Cell Mol Life Sci* 2009, 66(16):2759-2771

Ferko N, Levine MAH. Evaluation of the association between St. John's wort and elevated thyroid-stimulating hormone. *Pharmacother* 2001, 21: 1574-1578

Fiebich BL, Knörle R, Appel K, Kammler T, Weiss G. Pharmacological studies in an herbal drug combination of St. John's Wort (*Hypericum perforatum*) and passion flower (*Passiflora incarnata*): *in vitro* and *in vivo* evidence of synergy between *Hypericum* and *Passiflora* in antidepressant pharmacological models. *Fitoterapia* 2011, 82(3):474-480

Findling RL, McNamara NK, O'Riordan MA, Reed MD, Demeter CA, Branicky LA, et al. An open-label pilot study of St. John's wort in juvenile depression. *J Am Acad Child Adolesc Psychiatry* 2003, 42:908-914

Flausino OA Jr, Zangrossi H Jr, Salgado JV, Viana MB. Effects of acute and chronic treatment with *Hypericum perforatum* L. (LI 160) on different anxiety-related responses in rats. *Pharmacol Biochem Behav* 2002, 71:251-257

Fogle RH, Murphy PA, Westhoff CL, Stanczyk FZ. Does St. John's wort interfere with the antiandrogenic effect of oral contraceptive pills? *Contraception* 2006, 74: 245-248

Fornal CA, Metzler CW, Mirescu C, Stein SK, Jacobs BL. Effects of standardized extracts of St. John's wort on the single-unit activity of serotonergic dorsal raphe neurons in awake cats: comparison with fluoxetine and sertraline. *Neuropsychopharmacol* 2001, 25: 858-870

Fox E, Murphy RF, McCully CL, Adamson PC. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. *Cancer Chemother Pharmacol* 2001, 47:41-44

Friede M, Hasenfuss I, Wüstenberg P. Alltagssicherheit eines pflanzlichen Antidepressivums aus Johanniskraut. *Fortschr Medizin* 1998, 116:131-135

- Friede M, Henneicke von Zepelin HH, Freudenstein J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. *Pharmacopsychiatry* 2001, 34:38-41
- Froestl B, Steiner B, Muller WE. Enhancement of proteolytic processing of the beta-amyloid precursor protein by hyperforin. *Biochem Pharmacol* 2003, 66:2177-2184
- Froushani SMA, Galee HEG, Khamisabadi M, Lotfallahzade B. Immunomodulatory effects of hydroalcoholic extract of *Hypericum perforatum*. *Avicenna J Phytomed* 2015, 5:62-68
- Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. *Clin Pharmacol Ther* 2004, 76:323-329
- Fukunaga K, Orito K. Time-course effects of St John's wort on the pharmacokinetics of cyclosporine in dogs: interactions between herbal extracts and drugs. *J Vet Pharmacol Ther* 2012, 35(5):446-451
- Fuller S, Richard AJ, Ribnicky DM, Beyl R, Mynatt R, Stephens JM. St. John's wort has metabolically favorable effects on adipocytes *in vivo*. *Evid Based Complement Alternat Med* 2014, article ID 862575, 8 pages
- Gahr M, Zeiss R, Lang D, Connemann BJ, Hiemke C, Freudenmann RW, *et al*. Risk of bleeding related to selective and non-selective serotonergic antidepressants: a case/non-case approach using data from two pharmacovigilance databases. *Pharmacopsychiatry* 2015, 48(1):19-24
- Galeotti N, Ghelardini C. St. John's wort relieves pain in an animal model of migraine. *Eur J Pain* 2013a, 17(3):369-381
- Galeotti N, Ghelardini C. St. John's wort reversal of meningeal nociception: a natural therapeutic perspective for migraine pain. *Phytomed* 2013b, 20(10):930-938
- Galeotti N, Ghelardini C. Reversal of NO-induced nociceptive hypersensitivity by St. John's wort and hypericin: NF- κ B, CREB and STAT1 as molecular targets. *Psychopharmacol* 2013c, 227(1):149-163
- Galeotti N, Farzad M, Bianchi E, Ghelardini C. PKC-mediated potentiation of morphine analgesia by St. John's wort in rodents and humans. *J Pharmacol Sci* 2014, 124:409-417
- Galeotti N, Vivoli E, Bilia AR, Vincieri FF, Ghelardini C. St. John's Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase C γ and epsilon activity. *Biochem Pharmacol* 2010, 79(9):1327-1336
- Gao S, Jiang W, Yin T, Hu M. Highly variable contents of phenolics in St. John's Wort products affect their transport in the human intestinal Caco-2 cell model: pharmaceutical and biopharmaceutical rationale for product standardization. *J Agric Food Chem* 2010, 58(11):6650-6659
- Garrovo C, Rosati A, Bartoli F, Decorti G. St John's wort modulation and developmental expression of multidrug transporters in the rat. *Phytother Res* 2006, 20:468-473
- Gastpar M, Singer A, Zeller K. Efficacy and tolerability of *Hypericum* extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. *Pharmacopsychiatry* 2005, 38:78-86
- Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of *Hypericum* extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. *Pharmacopsychiatry* 2006, 39:66-75
- Gastpar M, Zeller K. *Hypericum*-Extrakt STW3 und Sertralin zur Behandlung der mittelschweren Depression. *Psychopharmakother* 2005, 12:146-153

- Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, Menegazzi M, *et al.* *Hypericum perforatum* attenuates the development of cerulein-induced acute pancreatitis in mice. *Shock* 2006a, 25:161-167
- Genovese T, Mazzon E, Menegazzi M, Di Paola R, Muia C, Crisafulli C, *et al.* Neuroprotection and enhanced recovery with *Hypericum perforatum* extract after experimental spinal cord injury in mice. *Shock* 2006b, 25:608-617
- Gerlach S. *Hypericum*. PhD Thesis, University Vienna 2008
- Ghazanfarpour M, Kaviani M, Asadi N, Ghaffarpassand F, Ziyadlou S, Tabatabaee HR, *et al.* *Hypericum perforatum* for the treatment of premenstrual syndrome. *Int J Gynaecol Obstet* 2011, 113(1):84-85
- Gibon J, Deloulme JC, Chevallier T, Ladevèze E, Abrous DN, Bouron A. The antidepressant hyperforin increases the phosphorylation of CREB and the expression of TrkB in a tissue-specific manner. *Int J Neuropsychopharmacol* 2013, 16(1):189-198
- Girzu M, Carnat A, Privat AM, Fialip J, Carnat AP, Lamaison JL. Sedative activity in mice of a hydroalcohol extract of *Hypericum perforatum*. *Phytother Res* 1997, 11:395-397
- Gobbi M, Moia M, Pirona L, Morizzoni P, Minnini T. *In vitro* binding studies with two *Hypericum perforatum* extracts – hyperforin, hypericin and biapigenin-on 5-HT₆, 5-HT₇, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. *Pharmacopsychiatry* 2001, 34. Suppl. 1:45-48 (abstract only)
- Goey AK, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, *et al.* The effect of St John's wort on the pharmacokinetics of docetaxel. *Clin Pharmacokinet* 2014, 53(1):103-110
- Gómez del Rio MA, Sánchez Reus MI, Iglesias I, Pozo MA, García Arencibia M, Fernández Ruiz J, *et al.* Neuroprotective Properties of Standardized Extracts of *Hypericum perforatum* on Rotenone Model of Parkinson's Disease. *CNS Neurol Disord Drug Targets* 2013, 12(5):665-679
- Gonzalez CL, Christensen HD, Rayburn WF, Coleman FH. Impact of antenatal *Hypericum* (St. John's wort) exposure on cognition in mice. *Neurobehavioral Teratology Societys abstracts* 1999, 328
- Gordon JB. SSRIs and St. John's wort: possible toxicity? *Am Acad Fam Physician* 1998, 57:950
- Gordon RY, Becker DJ, Rader DJ. Reduced efficacy of rosuvastatin by St. John's Wort. *Am J Med* 2009, 122(2): e1-e2, in press, doi: 10.1016/j.amjmed.2008.09.033
- Greeson JM, Sanford B, Monti DA. St. John's wort (*Hypericum perforatum*): a review of the current pharmacological, toxicological, and clinical literature. *Psychopharmacol* 2001, 153:402-414
- Gregoretti B, Stebel M, Candussio L, Crivellato E, Bartoli F, Decorti G. Toxicity of *Hypericum perforatum* (St. John's wort) administered during pregnancy and lactation in rats. *Toxicol Appl Pharmacol* 2004, 200:201-205
- Grobler AC, Matthews G, Molenberghs G. The impact of missing data on clinical trials: a re-analysis of a placebo controlled trial of *Hypericum perforatum* (St Johns wort) and sertraline in major depressive disorder. *Psychopharmacol* 2014, 231(9):1987-1999
- Grube B, Walper A, Wheatley D. St. John's Wort extract: efficacy for menopausal symptoms of psychological origin. *Adv Ther* 1999, 16:177-186 (abstract only)
- Grube B, Schermuck S, Hopfenmüller W, Michel F. 1997. Use of a hypericum extract in mild, transient depressive disorders. Monitoring demonstrates successful outcome of treatment and very good tolerability. *Eur J Clin Res* 1997, 9:293-302

- Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. Medical Economics Company, Montvale 2004
- Grundmann O, Kelber O, Butterweck V. Effects of St. John's wort extract and single constituents on stress-induced hyperthermia in mice. *Planta Med* 2006, 72:1366-1371
- Grundmann O, Lv Y, Kelber O, Butterweck V. Mechanism of St. John's wort extract (STW3-VI) during chronic restraint stress is mediated by the interrelationship of the immune, oxidative defense, and neuroendocrine system. *Neuropharmacol* 2010, 58(4-5):767-773
- Grush LR, Nierenberg A, Keefe B, Cohen LS. St. John's wort during pregnancy. *JAMA* 1998, 280:1566
- Guo JM, Lin P, Duan JA, Shang EX, Qian DW, Tang YP. Application of microdialysis for elucidating the existing form of hyperoside in rat brain: comparison between intragastric and intraperitoneal administration. *J Ethnopharmacol* 2012, 144(3):664-670
- Gurley BJ, Grdner SF, Hubbard MA, Williams DK, Brooks Gentry W, Cui J, et al. Clinical assessment of effects of botanical supplementaion on cytochrome P450 phenotypes in the elderly. *Drugs Aging* 2005, 22:525-539
- Gutmann H, Bruggisser R, Schaffner W, Bogman K, Botomino A, Drewe J. Transport of amentoflavone across the blood-brain barrier *in vitro*. *Planta Med* 2002, 68:804-807
- Haag SF, Tscherch K, Arndt S, Kleemann A, Gersonde I, Lademann J, et al. Enhancement of skin radical scavenging activity and stratum corneum lipids after the application of a hyperforin-rich cream. *Eur J Pharm Biopharm* 2014, 86(2):227-233
- Häberlein H, Prenner L, Zeller K. Einfluss von Hyperosid und Hyperforin auf die Regulation und laterale Mobilität von beta1-adrenergen Rezeptoren an lebenden C6-Glioblastomzellen: ein postsynaptischer Ansatz zum Wirkmechanismus von Johanniskraut. *Z Phytother* 2008, 29:S8
- Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, et al. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. *Clin Pharmacol Ther* 2010, 87(2):191-196
- Halicioglu K, Çörekçi B, Akkaş İ, Irgin C, Özcan F, Yilmaz F, et al. Effect of St John's wort on bone formation in the orthopaedically expanded premaxillary suture in rats: a histological study. *Eur J Orthod* 2015, 37(2):164-169
- Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, et al. The interaction between ST. John's wort and an oral contraceptive. *Clin Pharmacol Ther* 2003, 74:525-535
- Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, et al. St. John's wort: A systematic review of adverse effects and drug interactions for the consultation psychiatrist. *Psychosomatics* 2003, 44:271-282
- Hänsel R, Keller K, Rimpler H, Schneider G. Drogen E-O. Springer Verlag, Berlin 1993
- Hänsel R, Sticher O. Pharmakognosie – Phytopharmazie. Springer Medizin Verlag, Heidelberg, 2015
- Hängsen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the Hypericum extract LI 160. *J Geriatr Psychiatr Neurol* 1994, 7:S15-S18
- Hängsen KD, Vesper J. Antidepressive Wirksamkeit eines hochdosierten Hypericum-Extrakts. *Münchener Medizinische Wochenschrift* 1996, 138:29-33

Hansen RS, Paulsen I, Davies M. Determinants of amentoflavone interaction at the GABA_A receptor. *Eur J Pharmacol* 2005, 519:199-207

Harrer G, Hübner WD, Podzuweit H. Effectiveness and tolerance of the Hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. *J Geriatr Psychiatr Neurol* 1994, 7:24-28

Harrer G, Sohmidt K, Kuhn K, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. *Arzneim-Forsch/Drug Res* 1999, 49:289-296

Hasanein P, Shahidi S. Effects of *Hypericum perforatum* extract on diabetes-induced learning and memory impairment in rats. *Phytother Res* 2011, 25(4):544-549

Hatanaka J, Shinme Y, Kuriyama K, Uchida A, Kou K, Uchida S, et al. *In vitro* and *in vivo* characterization of new formulations of St. John's Wort extract with improved pharmacokinetics and anti-nociceptive effect. *Drug Metab Pharmacokinet* 2011, 26(6):551-558

Hatano T, Sameshima Y, Kawabata M, Yamada S, Shinozuka K, Nakabayashi T, et al. St. John's wort promotes adipocyte differentiation and modulates NF- κ B activation in 3T3-L1 cells. *Biol Pharm Bull* 2014, 37(7):1132-1138

Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John's wort (*Hypericum perforatum*) on tacrolimus pharmacokinetics in healthy volunteers. *J Clin Pharmacol* 2004, 44:89-94

Heinrich M, Vikuk V, Daniels R, Stintzing FC, Kammerer DR. Characterization of *Hypericum perforatum* L. (St. John's wort) macerates prepared with different fatty oils upon processing and storage. *Phytochem Lett* 2017, 20:470-480

Hellenbrand N, Lechtenberg M, Petereit F, Sendker J, Hensel A. Isolation and Quantification of Oligomeric and Polymeric Procyanidins in the Aerial Parts of St. John's Wort (*Hypericum perforatum*). *Planta Med* 2015, 81:1175-1181

Helmja K, Vaher M, Püssa T, Orav A, Viitak A, Levandi T, et al. Variation in the composition of the essential oils, phenolic compounds and mineral elements of *Hypericum perforatum* L. growing in Estonia. *Nat Prod Res* 2011, 25(5):496-510

Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (*Hypericum perforatum*): Drug interactions and clinical outcomes. *Br J Clin Pharmacol* 2002, 54:349-356

Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, et al. St John's wort increases expression of P-glycoprotein: implications for drug interactions. *Br J Clin Pharmacol* 2002, 53:75-82

Herberg KW. Alternative zu synthetischen Psychopharmaka? *Therapiewoche* 1994, 44:704-713

Hicks SM, Walker AF, Gallagher J, Middleton RW, Wright J. The significance of "nonsignificance" in randomized controlled studies: a discussion inspired by a double-blinded study on St. John's wort (*Hypericum perforatum* L.) for premenstrual symptoms. *J Altern Complement Med* 2004, 10:925-932

Higuchi A, Yamada H, Yamada E, Jo N, Matsumura M. Hypericin inhibits pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy. *Mol Vis* 2008, 14:249-254

Ho YF, Huang DK, Hsueh WC, Lai MY, Yu HY, Tsai TH. Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts. *Life Sci* 2009, 85(7-8):296-302

Hoffmann F, Glaeske G, Petermann F, Bachmann CJ. Outpatient treatment in German adolescents with depression: an analysis of nationwide health insurance data. *Pharmacoepidemiol Drug Saf* 2012, 21(9):972-979

- Hoffmann J, Kühl ED. Therapie von depressiven Zuständen mit Hypericum. *Ztschr Allgmed* 1979, 55:776-782
- Hofrichter J, Krohn M, Schumacher T, Lange C, Feistel B, Walbroel B, et al. Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. *Curr Alzheimer Res* 2013, 10(10):1057-1069
- Hohmann MS, Cardoso RD, Fattori V, Arakawa NS, Tomaz JC, Lopes NP, et al. *Hypericum perforatum* Reduces Paracetamol-Induced Hepatotoxicity and Lethality in Mice by Modulating Inflammation and Oxidative Stress. *Phytother Res* 2015, 29:1097-1101
- Hohmann N, Maus A, Carls A, Haefeli WE, Mikus G. St. John's wort treatment in women bears risks beyond pharmacokinetic drug interactions. *Arch Toxicol* 2016, 90:1013-1015
- Hojo Y, Echizenya M, Ohkubo T, Shimizu T. Drug interaction between St John's wort and zolpidem in healthy subjects. *J Clin Pharm Ther* 2011, 36(6):711-715
- Hokkanen J, Tolonen A, Mattila S, Turpeinen M. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. *Eur J Pharm Sci* 2011, 42(3):273-284
- Holme S A, Roberts D L. Erythroderma associated with St John's wort. *Br J Dermatol* 2000, 143:1127-1128
- Holsboer-Trachsler E, Vanoni C. Wirksamkeit und Verträglichkeit des Hypericum-Spezialextraktes LI 160 bei depressiven Verstimmungen - eine ambulante Anwendungsbeobachtung. *Schweiz Rundsch Med Prax* 1999, 88:1475-1480
- Hu Z, Yang X, Ho PCL, Chan E, Chan SY, Xu C, et al. St. John's wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. *Pharm Res* 2005, 23:902-914
- Huang N, Rizshsky L, Hauck C, Nikolau BJ, Murphy PA, Birt DF. Identification of anti-inflammatory constituents in *Hypericum perforatum* and *Hypericum gentianoides* extracts using RAW 264.7 mouse macrophages. *Phytochemistry* 2011, 72(16):2015-2023
- Huang N, Rizshsky L, Hauck CC, Nikolau BJ, Murphy PA, Birt DF. The inhibition of lipopolysaccharide-induced macrophage inflammation by 4 compounds in *Hypericum perforatum* extract is partially dependent on the activation of SOCS3. *Phytochemistry* 2012, 76:106-116
- Huang N, Singh N, Yoon K, Loiacono CM, Kohut ML, Birt DF. The immuno-regulatory impact of orally-administered *Hypericum perforatum* extract on Balb/C mice inoculated with H1n1 influenza A virus. *PLoS One* 2013, 8(9):e76491
- Hübner WD, Kirste T. Experience with St John's Wort (*Hypericum perforatum*) in children under 12 years with symptoms of depression and psychovegetative disturbances. *Phytother Res* 2001, 15:367-370
- Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2014, in press, doi: 10.1002/14651858.CD000031.pub4
- Husain GM, Chatterjee SS, Singh PN, Kumar V. Beneficial effect of *Hypericum perforatum* on depression and anxiety in a type 2 diabetic rat model. *Acta Pol Pharm* 2011a, 68(6):913-918
- Husain GM, Chatterjee SS, Singh PN, Kumar V. Hypolipidemic and Antiobesity-Like Activity of Standardised Extract of *Hypericum perforatum* L. in Rats. *ISRN Pharmacol* 2011b, 2011:505247
- Husain GM, Singh PN, Kumar V. Beneficial effects of a standardized *Hypericum perforatum* extract in rats with experimentally induced hyperglycemia. *Drug Discov Ther* 2009, 3(5):215-220

- Hypericum Depression Trial Study Group. Effect of *Hypericum perforatum* (St John's wort) in major depressive disorder: a randomized controlled trial. *JAMA* 2002, 287:1807-1814
- Ima H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakan S, et al. The recovery time-course of CYP3A after induction by St John's wort administration. *Br J Clin Pharmacol* 2008, 65:701-707
- Ioachim E, Lampri E. Hepatocellular carcinoma with syncytial giant cell in an adult with alcoholic cirrhosis after consumption of *hypericum perforatum* / St. John's wort. *Virchows Arch* 2009, 455(1):S432
- Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John's Wort. *J.Clin Anesth* 2000, 12:498-499
- Irion H. Drogisten-Lexikon. Springer Verlag, Berlin/Göttingen/Heidelberg 1955
- Ivetic V, Popovic M, Mimica-Dukic N, Barak O, Pilija V. St. John's wort (*Hypericum perforatum* L.) and kindling epilepsy in rabbit. *Phytomed* 2002, 9:496-499
- Ivetic V, Trivic S, Pogancev MK, Popovic M, Zlinská J. Effects of St John's wort (*Hypericum perforatum* L.) extracts on epileptogenesis. *Molecules* 2011, 16(9):8062-8075
- Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. *Med Princ Pract* 2012, 21:404-428
- Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. An updated systematic review. *Drugs* 2009, 69:1777-1798
- Jackson A, D'Avolio A, Moyle G, Bonora S, Di Perri G, Else L, et al. Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. *J Antimicrob Chemother* 2014, 69(7):1911-1915
- Jacobson J M, Feinman L, Liebes L, Ostrow N, Koslowski V, Tobia A, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. *Antimicrob Agents Chemother* 2001, 45:517-524
- Jakobs D, Hage-Hülsmann A, Prenner L, Kolb C, Weiser D, Häberlein H. Downregulation of $\beta 1$ -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John's wort. *J Pharm Pharmacol* 2013, 65(6):907-915
- Jendželovská Z, Jendželovský R, Hil'ovská L, Koval' J, Mikeš J, Fedoročko P. Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells. *Toxicol In Vitro* 2014, 28(7):1259-1273.
- Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of *Hypericum perforatum* L. in biochemical models of antidepressant activity. *Life Sci* 2001, 68:1593-1605
- Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2004, 57:592-599
- Johne A, Brockmüller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort. *Clin Pharmacol Ther* 1999, 66:338-345
- Johne A, Brockmüller J, Bauer S, Mai I, Schneider J, Lenzen-Grossimlinghaus R, et al. St. John's wort extract and liver cirrhosis. *Clin Pharmacol Therap* 2002a, 71:P95

- Johne A, Schmider J, Brockmüller J, Stadelmann AM, Störmer E, Bauer S, *et al.* Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (*Hypericum perforatum*). *J Clin Psychopharmacol* 2002b, 22:46-54
- Johne A, Perloff ES, Bauer S, Schmider J, Mai I, Brockmüller J, *et al.* Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. *Eur J Clin Pharmacol* 2004, 60:617-622
- Johnson D, Siebenhüner G, Hofer E, Sauerwein-Giese E, Frauendorf A. Einfluss von Johanniskraut auf die ZNS-Aktivität. *TW Neurol Psychiatr* 1992, 6:436-444
- Jones D, Tourian L, Margolese HC. Possible association of syndrome of inappropriate secretion of antidiuretic hormone with St. John's wort use. *J Clin Psychopharmacol* 2014, 34(6):1-2
- Juergeniemi G, Boje K, Huewel S, Lohmann C, Galla HJ, Nahrstedt A. *In vitro* studies indicate that miquelianin (quercetin 3-O-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. *Planta Med* 2003, 69:1013-1017
- Jungke P, Ostrow G, Li JL, Norton S, Nieber K, Kelber O, *et al.* Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John's wort extract (STW 3-VI) and fluoxetine. *Psychopharmacol* 2011, 213(4):757-772
- Kacerovská D, Pizinger K, Majer F, Smíd F. Photodynamic therapy of nonmelanoma skin cancer with topical *hypericum perforatum* extract--a pilot study. *Photochem Photobiol* 2008, 84(3):779-785
- Kaehler ST, Sinner C, Chatterjee SS, Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. *Neurosci Lett* 1999, 262:199-202
- Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of *Hypericum* extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. *Pharmacopsychiatry* 2001, 34:96-103
- Kaltschmidt B, Heinrich M, Kaltschmidt C. Stimulus-dependent activation of NF-kappaB specifies apoptosis or neuroprotection in cerebellar granule cells. *Neuromolecular Med* 2002, 2:299-309
- Karalapillai DC, Bellomo R. Convulsions associated with an overdose of St. John's wort. *Med J Austr* 2007, 186:213-214
- Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of *Hypericum perforatum* (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. *J.Hepatol* 2000, 33:853-855
- Kasper S, Angheliescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial. *BMC Med* 2006, 4:14
- Kasper S, Angheliescu IG, Szegedi A, Dienel A, Kieser M. Placebo controlled continuation treatment with *Hypericum* extract WS 5570 after recovery from a mild to moderate depressive episode. *Wien Med Wochenschr* 2007, 15:13-14
- Kasper S, Gastpar M, Möller HJ, Müller WE, Volz HP, Dienel A, *et al.* Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. *Int Clin Psychopharmacol* 2010, 25(4):204-213
- Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M. Continuation and long-term maintenance treatment with *Hypericum* extract WS 5570 after recovery from an acute episode of moderate depression – A

double-blind, randomized, placebo controlled long-term trial. *Eur Neuropsychopharmacol* 2008, 18:803-813

Kawaguchi A, Ohmori M, Tsuruoka SI, Nishiki K, Harada K, Miyamori I, *et al.* Drug interaction between St John's wort and quazepam. *Br J Clin Pharmacol* 2004, 58:403-410

Khalifa AE. *Hypericum perforatum* as a nootropic drug: enhancement of retrieval memory of a passive avoidance conditioning paradigm in mice. *J Ethnopharmacol* 2001, 76:49-57

Khalili M, Jalali MR, Mirzaei-Azandaryani M. Effect of hydroalcoholic extract of *Hypericum perforatum* L. leaves on ethylene glycol-induced kidney calculi in rats. *Urol J* 2012, 9(2):472-479

Khan M, Subhan F, Khan AU, Abbas M, Ali G, Rauf K, *et al.* Nature cures nature: *Hypericum perforatum* attenuates physical withdrawal signs in opium dependent rats. *Pharm Biol* 2014, 52(5):586-590

Kiasalari Z, Baluchnejadmojarad T, Roghani M. *Hypericum Perforatum* Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastratial 6-Hydroxydopamine Rat Model of Parkinson's Disease. *Cell Mol Neurobiol* 2016, 36:521-530

Kientsch U, Bürgi S, Ruedeberg C, Probst S, Honegger UE. St. John's wort extract Ze 117 (*Hypericum perforatum*) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces 3-adrenoceptor numbers on cultured rat brain cells. *Pharmacopsychiatry* 2001, 34, Suppl. 1:56-60 (abstract only)

Kitikannakorn N, Chaiyakunapruk N, Nimpitakpong P, Dilokthornsakul P, Meepoo E, Kerdpeng W. An overview of the evidences of herbals for smoking cessation. *Complement Ther Med* 2013, 21(5):557-564

Klier CM, Schäfer MR, Schmid-Siegel B, Lenz G, Mannel M. St. John's wort (*Hypericum perforatum*) – is it safe during breastfeeding? *Pharmacopsychiatry* 2002, 35:29-30

Klier CM, Schmid-Siegel B, Schafer MR, Lenz G, Saria A, Lee A, *et al.* John's wort (*Hypericum perforatum*) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants. *J Clin Psychiatry* 2006, 67:305-309

Klusa V, Germane S, Nöldner M, Chatterjee SS. *Hypericum* extract and hyperforin: memory-enhancing properties in rodents. *Pharmacopsychiatry* 2001, 34:61-69

Kobak KA, Taylor LVH, Bystritsky A, Kohlenberg CJ, Greist JH, Tucker P, *et al.* St John's wort versus placebo on obsessive-compulsive disorder: results form a double-blind study. *Int Clin Psychopharmacol* 2005, 20: 299-304

Kobak KA, Taylor LVH, Warner G, Futterer R. St. John's wort versus placebo in social phobia. *J Clin Psychopharmacol* 2005a, 25:51-58

Koerberle A, Rossi A, Bauer J, Dehm F, Verotta L, Northoff H, *et al.* Hyperforin, an anti-inflammatory constituent from St. John's wort, inhibits microsomal prostaglandin E₂ synthase-1 and suppresses prostaglandin E₂ formation *in vivo*. *Front Pharmacol* 2011, 2:7

Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. *Clin. Cancer Res* 2005, 11:6972-6979

Köppel H, Naser B, Schulz HU, Kibbel T, Schürer M, Liske E. Investigation of the effect on phytosensitivity following repeated oral dosing of *Hypericum* extract in 20 healthy male and female volunteers. *Kongressband Phytopharmaka Phytotherapie* 2008, 28

- Kolding L, Pedersen LH, Henriksen TB, Olsen J, Grzeskowiak LE. *Hypericum perforatum* use during pregnancy and pregnancy outcome. *Reprod Toxicol* 2015, 58:234-237; erratum: *Reprod Toxicol* 2016, 59:183
- Kraus B, Wolff H, Elstner EF, Heilmann J. Hyperforin is a modulator of inducible nitric oxide synthase and phagocytosis in microglia and macrophages. *Naunyn Schmiedebergs Arch Pharmacol* 2010, 381(6):541-553
- Kresimon J, Kiencke P, Viehmann K, Kolb C, Müller J, Rychlik R. Medical care of patients with moderate depression under *Hypericum* extract STW3-VI compared to SSRI in routine outpatient treatment. *Gesundh ökon Qual manag* 2012, 17:198-206
- Ku SK, Kwak S, Kwon OJ, Bae JS. Hyperoside inhibits high-glucose-induced vascular inflammation *in vitro* and *in vivo*. *Inflammation* 2014, 37(5):1389-1400
- Kumar N, Husain GM, Singh PN, Kumar V. Antiaggressive activity of hyperforin: A preclinical study. *Drug Discov Ther* 2009, 3(4):162-167
- Kumar V, Mdzinarishvili A, Kiewert C, Abbruscato T, Bicket U, van der Schyl CJ, *et al.* NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's wort. *J Pharmacol Sci* 2006, 102:47-54
- Kumar V, Singh PN, Muruganandam AV, Bhattacharya SK. Effect of Indian *Hypericum perforatum* Linn on animal models of cognitive dysfunction. *J Ethnopharmacol* 2000, 72:119-128
- Kwon J, Oh KS, Cho S-Y, Bang MA, Kim HS, Vaidya B, *et al.* Estrogenic activity of hyperforine in MCF-7 Human Breast Cancer Cells Transfected with Estrogen Receptor. *Planta Med* 2016, 82:1425-1430
- Laakmann G, Dienel A, Kieser M. Clinical significance of hyperforin for the efficacy of *Hypericum* extracts on depressive disorders of different severities. *Phytomed* 1998, 5(6):435-442
- Laakmann E, Grajecki D, Doege K, zu Eulenburg C, Buhling KJ. Efficacy of *Cimicifuga racemosa*, *Hypericum perforatum* and *Agnus castus* in the treatment of climacteric complaints: a systematic review. *Gynecol Endocrinol* 2012, 28(9):703-709 (abstract only)
- Laakmann G, Schüle C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. *Pharmacopsychiatry* 1998a, 31:54-59
- Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of d-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* 2001, 144:916-917
- Lampri ES, Ioachim E, Harissis H, Balasi E, Mitselou A, Malamou-Mitsi V. Pleomorphic hepatocellular carcinoma following consumption of *hypericum perforatum* in alcoholic cirrhosis. *World J Gastroenterol* 2014, 20(8):2113-2116
- Lane-Brown ML. Photosensitivity associated with herbal preparations of St John's wort (*Hypericum perforatum*). *Med J Austral* 2000, 172:302
- Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. *J Geriatr Psychiatry Neurol* 1999, 12:7-10
- Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. *J Cardiovasc Pharmacol* 2011, 57(1):86-93

- Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. *Am J Psychiatry* 2002, 159:1361-1366
- Lee A, Minhas R, Matsuda N, Lam M, Ito S. The safety of St. John's wort (*Hypericum perforatum*) during breastfeeding. *J Clin Psychiatry* 2003, 64:966-968
- Lei HP, Yu XY, Xie HT, Li HH, Fan L, Dai LL, et al. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. *Xenobiotica* 2010, 40(4):275-281
- Lemmer W, von den Driesch V, Klieser E. Johanniskraut-Spezialextrakt WS 5572 bei leichter bis mittelschwerer Depression. *Fortschr Medizin* 1999, 117:143-154
- Lenoir S, Degenring FH, Saller R. A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of *Hypericum perforatum* L. *Phytomed* 1999, 6:141-146
- Leuner K, Li W, Amaral MD, Rudolph S, Calfa G, Schuwald AM, et al. Hyperforin modulates dendritic spine morphology in hippocampal pyramidal neurons by activating Ca (2+) – permeable TRPC6 channels. *Hippocampus*. 2013, 23(1):40-52
- Leuschner J. Preclinical toxicological profile of *Hypericum* extract LI 160. Abstracts of the 2nd International Conference on Phytomedicine, Munich 1996, SL 80
- L'homme RFA, Dijkema T, van der Ven AJAM, Burger DM. Enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. *J Acquir Immune Defic Syndr* 2006, 43:193-196
- Linde K, Berner M, Egger M, Mulrow C. St John's wort for depression: meta-analysis of randomised controlled trials. *Br J Psychiatry* 2005, 186:99-107
- Linde K. Johanniskraut bei Depression – eine Übersicht der randomisierten Studien bezogen auf einzelne Extrakte. Available at: http://www.phytotherapie-komitee.de/Forschung/kfn_hyperic_281206.pdf. Accessed 2007.
- Linde K, Berner MM, Kriston L. St. John's wort for major depression (review). *Cochrane Database of Syst Rev* 2008, 4: Art. No. CD000448, in press, doi: 10.1002/14651858. CD 000448. Pub3. 2008
- List PH, Hörhammer L. Hager's Handbuch der pharmazeutischen Praxis. Springer Verlag, Berlin/Heidelberg 1976
- Liu YR, Jiang YL, Huang RQ, Yang JY, Xiao BK, Dong JX. *Hypericum perforatum* L. preparations for menopause: a meta-analysis of efficacy and safety. *Climacteric* 2014, 17(4):325-335
- Lorusso G, Vannini N, Sogno I, Generoso L, Garbisa S, Noonan DM, et al. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. *Eur J Cancer* 2009, 45(8):1474-1484
- Lu YH, Du CB, Liu JW, Hong W, Wei DZ. Neuroprotective effects of *Hypericum perforatum* on trauma induced by hydrogen peroxide in PC12 cells. *Am J Chin Med* 2004, 32:397-405
- Lundahl A, Hedeland M, Bondesson U, Knutson L, Lennernäs H. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. *Eur J Pharm Sci* 2009, 36:433-443
- Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. *Eur J Clin Pharmacol* 2006, 62:225-233
- Madaus G. Lehrbuch der biologischen Heilmittel. Band II. Georg Thieme Verlag, Leipzig 1938

- Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, *et al.* Hyperforin content determines the magnitude of the St. John's wort – cyclosporine drug interaction. *Clin Pharmacol Ther* 2004, 76:330-340
- Mai I, Störmer E, Bauer S, Krüger H, Budde K, Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. *Nephrol Dial Transplant* 2003, 18:819-822
- Maisenbacher P, Kovar KA. Analysis and stability of Hyperici oleum. *Planta Med* 1992, 58:351-354
- Mannel M, Kuhn U, Schmidt U, Ploch M, Murck H. St. John's wort extract LI160 for the treatment of depression with atypical features – a double-blind, randomized, and placebo-controlled trial. *J Psychiatr Res* 2010, 44(12):760-767
- Mannucci C, Pieratti A, Firenzuoli F, Caputi AP, Calapai G. Serotonin mediates beneficial effects of *Hypericum perforatum* on nicotine withdrawal signs. *Phytomed* 2007, 14:645-651
- Markert C, Kastner IM, Hellwig R, Kalafut P, Schweizer Y, Hoffmann MM, *et al.* The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. *Basic Clin Pharmacol Toxicol* 2015, 116:423-428
- Markert C, Ngui P, Hellwig R, Wirsching T, Kastner IM, Riedel KD, *et al.* Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan. *Int J Clin Pharmacol Ther* 2014, 52(4):328-336
- Martinez B, Kasper S, Ruhrmann S, Möller HJ. Hypericum in the treatment of seasonal affective disorders. *J.Geriatr.Psychiatry Neurol* 1994, 7 Suppl. 1:S29-S33
- Mathijssen RHJ, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan Metabolsim. *J Natl Cancer Inst* 2002, 94:1247-1249
- Maurer A, Johne A, Bauer S, Brockmüller J, Donath F, Roots I, *et al.* Interaction of St. John's wort extract with phenprocoumon. *Eur.J.Clin.Pharmacol* 1999, 55:A22
- Maury W, Price JP, Brindley MA, Oh C, Neighbors JD, Wiemer DF, *et al.* Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of *Hypericum perforatum*. *Virol J* 2009, 6:101
- Meier B. Vergleichbarkeit von Phytopharmaka am Beispiel von Johanniskraut. In: Loew D, Blume H, Dingermann Th. *Phytopharmaka V*, Steinkopff, Darmstadt 1999
- Meinke MC, Schanzer S, Haag SF, Casetti F, Müller ML, Wölfl U, *et al.* *In vivo* photoprotective and anti-inflammatory effect of hyperforin is associated with high antioxidant activity *in vitro* and *ex vivo*. *Eur J Pharm Biopharm* 2012, 81(2):346-350
- Melzer J, Brignoli R, Keck ME, Saller R. A hypericum extract in the treatment of depressive symptoms in outpatients: an open study. *Forsch Komplementmed* 2010, 17(1):7-14
- Menegazzi M, Novelli M, Befly P, D'Aleo V, Tedeschi E, Lupi R, *et al.* Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line. *Int J Biochem Cell Biol* 2008,40(8):1509-1521
- Miadokova E, Chalupa I, Vickova V, Sevcovicova A, Nudova S, Kopaskova M, *et al.* Genotoxicity and antigenotoxicity evaluation of non-photoactivated hypericin. *Phytother Res* 2010, 24:90-95
- Micioni Di Bonaventura MV, Vitale G, Massi M, Cifani C. Effect of *Hypericum perforatum* Extract in an Experimental Model of Binge Eating in Female Rats. *J Obes* 2012, 2012:956137

- Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. *BMJ* 2004, 329:23-30
- Mohanasundari M, Sabesan M. Modulating effect of *Hypericum perforatum* extract on astrocytes in MPTP induced Parkinson's disease in mice. *Eur Rev Med Pharmacol Sci* 2007, 11:17-20
- Mohanasundari M, Srinivasan MS, Sethuopathy S, Sabesan M. Enhanced neuroprotective effect by combination of bromocriptine and *Hypericum perforatum* extract against MPTP-induced neurotoxicity in mice. *J Neurol Sci* 2006, 249:140-144
- Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. *Mol Psychiatry* 2011, 16(11):1088-1095
- Montgomery SA, Hübner WD, Grigoleit HG. Efficacy and tolerability of St. John's wort extract compared with placebo in patients with mild to moderate depressive disorder. *Phytomed* 2000, 7(Suppl. 2):107
- Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. *J Clin Pharmacol* 2004, 44:95-101
- Moretti ME, Maxson A, Hanna F, Koren G. Evaluating the safety of St. John's wort in human pregnancy. *Reprod Toxicol* 2009, 28:96-99
- Moretti ME, Maxson A, Hanna F, Koren G. The first data on the safety of *Hypericum perforatum* (St John's wort) in pregnant women. *Focus Altern Compl Ther* 2010, 15:20-21
- Mortensen T, Shen S, Shen F, Walsh MK, Sims RC, Miller CD. Investigating the effectiveness of St John's wort herb as an antimicrobial agent against mycobacteria. *Phytother Res* 2012, 26(9):1327-1333
- Moses EL, Mallinger AG. St. John's Wort: three cases of possible mania induction. *J Clin Psychopharmacol* 2000, 20:115-117
- Mozaffari S, Esmaily H, Rahimi R, Baeeri M, Sanei Y, Asadi-Shahmirzadi A, et al. Effects of *Hypericum perforatum* extract on rat irritable bowel syndrome. *Pharmacogn Mag* 2011, 7(27):213-223
- Mueller BM. St. John's wort for depressive disorders: results of an outpatient study with the *Hypericum* extract HYP811. *Adv Ther* 1998, 15:109-116
- Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. *Eur J Clin Pharmacol* 2006, 62:29-36
- Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, et al. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. *Eur J Clin Pharmacol* 2009, 65:81-87
- Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, et al. Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. *Clin Pharmacol Ther* 2004a, 75:546-557
- Müller T, Mannel M, Murck H, Rahlfs VW. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. *Psychosom Med* 2004b, 66:538-547
- Müller WE, Rolli M, Schäfer C, Hafner U. Effects of *Hypericum* extract (LI 160) in biochemical models of antidepressant activity. *Pharmacopsychiatry* 1997, 30(Suppl. 2):102-107

- Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. *Pharmacopsychiatry* 1998, 31(Suppl.):16-21
- Murck H, Spitznagel H, Ploch M, Seibel K, Schaffler K. Hypericum extract reverses S-ketamine-induced changes in auditory evoked potentials in humans - possible implications for the treatment of schizophrenia. *Biol Psychiatry* 2006, 59:440-445
- Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. *Contraception* 2005, 71:402-408
- Musselmann B, Rychlik R, Burkart M. Use of St. John's wort for depression in primary care - a non-interventional study. *MMW Fortschr Med Originalien* 2011, 153:119-127
- Nagai M, Fukamachi T, Tsujimoto M, Ogura K, Hiratsuka A, Ohtani H, *et al.* Inhibitory effects of herbal extracts on the activity of human sulfotransferase isoform sulfotransferase 1A3 (SULT1A3). *Biol Pharm Bull* 2009, 32:105-109
- Najafizadeh P, Hashemian F, Mansouri P, Farshi S, Surmaghi MS, Chalangari R. The evaluation of the clinical effect of topical St John's wort (*Hypericum perforatum* L.) in plaque type psoriasis vulgaris: a pilot study. *Australas J Dermatol* 2012, 53(2):131-135
- Nakamura K, Aizawa K, Yamauchi J, Tanoue A. Hyperforin inhibits cell proliferation and differentiation in mouse embryonic stem cells. *Cell Prolif* 2013, 46(5):529-537
- Naziroğlu M, Sahin M, Ciğ B, Aykur M, Erturan I, Ugan Y. *Hypericum perforatum* modulates apoptosis and calcium mobilization through voltage-gated and TRPM2 calcium channels in neutrophil of patients with Behcet's disease. *J Membr Biol* 2014a, 247(3):253-262
- Naziroglu M, Kutluhan S, Ovey IS, Aykur M, Yurekli VA. Modulation of oxidative stress, apoptosis, and calcium entry in leukocytes of patients with multiple sclerosis by *Hypericum perforatum*. *Nutr Neurosci* 2014b, 17(5):214-221
- Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. *Brain Res* 1999, 816:358-363
- Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. *Ann Pharmacother* 1999, 33:502
- Niederhofer H. St. John's wort may improve some symptoms of attention-deficit hyperactivity disorder. *Nat Prod Res* 2010, 24(3):203-205
- Niederhofer H. St John's Wort treating patients with autistic disorder. *Phytother Res* 2009, 23(11):1521-1523
- Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Laine K, *et al.* St John's wort greatly reduces the concentrations of oral oxycodone. *Eur J Pain* 2010, 14(8):854-859
- Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John's wort. *Biol.Psychiatry* 1999, 46:1707-1708
- Nöldner M, Schötz K. Rutin is essential for the antidepressant activity of *Hypericum perforatum* extracts in the forced swimming test. *Planta Med* 2002, 68:577-580

- Novelli M, Beffy P, Menegazzi M, De Tata V, Martino L, Sgarbossa A, *et al.* St. John's wort extract and hyperforin protect rat and human pancreatic islets against cytokine toxicity. *Acta Diabetol* 2014, 51(1):113-121
- O'Breasail AM, Argouarch S. Hypomania and St. John's wort. *Can J Psychiatry* 1998, 43:746-747
- Ocak Z, Acar M, Gunduz E, Gunduz M, Demircan K, Uyeturk U, *et al.* Effect of hypericin on the ADAMTS-9 and ADAMTS-8 gene expression in MCF7 breast cancer cells. *Eur Rev Med Pharmacol Sci* 2013, 17(9):1185-1190
- Okpanyi SN, Lizba H, Scholl BC, Miltenburger HG. Genotoxicity of a standardized Hypericum extract. *Arzneimittelforschung* 1990, 40:851-855
- Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. *Fertil Steril* 1999, 71:517-522
- Onoue S, Seto Y, Ochi M, Inoue R, Ito H, Hatano T, *et al.* *In vitro* photochemical and phototoxicological characterization of major constituents in St. John's Wort (*Hypericum perforatum*) extracts. *Phytochem* 2011, 72(14-15):1814-1820
- Orhan IE, Kartal M, Gülpinar AR, Yetkin G, Orlikova B, Diederich M, *et al.* Inhibitory effect of St. John's Wort oil macerates on TNF α -induced NF- κ B activation and their fatty acid composition. *J Ethnopharmacol* 2014, 155(2):1086-1092
- Orhan IE, Kartal M, Gülpinar AR, Cos P, Matheussen A, Maes L, *et al.* Assessment of antimicrobial and antiprotozoal activity of the olive oil macerate samples of *Hypericum perforatum* and their LC-DAD-MS analyses. *Food Chem* 2013, 138(2-3):870-875
- Osterheider M, Schmidtke A, Beckmann H. Behandlung depressiver Syndrome mit Hypericum (Johanniskraut) – Eine placebokontrollierte Doppelblindstudie. *Fortschr Neurol Psychiat* 1992, 60(S2):210-211
- Ott M, Huls M, Cornelius MG, Fricker G. St. John's Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier. *Pharm Res* 2010, 27(5):811-822
- Ozarowski A, Lancucki J, Gasiorowska K. Leki roślinne. Zjednoczenie Przemysły Zielarskiego. Herbapol, Warszawa 1978
- Özdemir ÜS, Nazıroğlu M, Şenol N, Ghazizadeh V. *Hypericum perforatum* Attenuates Spinal Cord Injury-Induced Oxidative Stress and Apoptosis in the Dorsal Root Ganglion of Rats: Involvement of TRPM2 and TRPV1 Channels. *Mol Neurobiol* 2016, 53:3540-3551
- Öztürk N, Korkmaz S, Ozturk Y. Wound-healing activity of St. John's Wort (*Hypericum perforatum* L.) on chicken embryonic fibroblasts. *J Ethnopharmacol* 2006, 111:33-39
- Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. *Life Sci* 2006, 78:2131-2145
- Parker V, Wong AHC, Boon HS, Seeman MV. Adverse reactions to St John's wort. *Can J Psychiatry* 2001, 46:77-79
- Parsons A, Ingram J, Inglis J, Aveyard P, Johnstone E, Brown K, *et al.* A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to prevent weight gain on smoking cessation. *Drug Alcohol Depend* 2009, 102(1-3):116-122
- Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's wort. *Am J Med* 2002, 112:507-508

- Paterniti I, Briguglio E, Mazzon E, Galuppo M, Oteri G, Cordasco G, *et al.* Effects of *Hypericum perforatum*, in a rodent model of periodontitis. *BMC Complement Altern Med* 2010, 10:73
- Paulke A, Nöldner M, Schubert-Zsilavec M, Wurglics M. St. John's wort flavonoids and their metabolites show antidepressant activity and accumulate in brain after multiple oral dose. *Pharmazie* 2008, 63:296-302
- Pavlovic M, Tzakou O, Petrakis PV, Couladis M. The essential oil of *Hypericum perforatum* L., *Hypericum tetrapterum* Fries and *Hypericum olympicum* L. growing in Greece. *Flav Fragr J* 2006, 21:84-87
- Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT. St John's wort greatly decreases the plasma concentrations of oral S-ketamine. *Fundam Clin Pharmacol* 2012, 26(6):743-750
- Pereira JC Jr, Pradella-Hallinan M, Alves RC. Saint John's wort, an herbal inducer of the cytochrome P4503A4 isoform, may alleviate symptoms of Willis-Ekbom's disease. *Clinics (Sao Paulo)* 2013, 68(4):469-474
- Perfumi M, Ciccocioppo R, Angeletti S, Cuculelli M, Massi M. Effects of *Hypericum perforatum* extraction on alcohol intake in Marchigian Sardinian alcohol-preferring rats. *Alcohol Alcohol* 1999, 34:690-698
- Perfumi M, Mattioli L, Cuculelli M, Massi M. Reduction of ethanol intake by chronic treatment with *Hypericum perforatum*, alone or combined with naltrexone in rats. *J Psychopharmacol* 2005a, 19:448-454
- Perfumi M, Mattioli L, Forti L, Massi M, Ciccocioppo R. Effect of *Hypericum perforatum* CO₂ extract on the motivational properties of ethanol in alcohol-preferring rats. *Alcohol Alcohol* 2005b, 40:291-296
- Perfumi M, Panocka I, Ciccocioppo R, Vitali D, Froidi R, Massi M. Effects of a methanolic extract and a hyperforin-enriched CO₂ extract of *Hypericum perforatum* on alcohol intake in rats. *Alcohol Alcohol* 2001, 36:199-206
- Perfumi M, Santoni M, Cippitelli A, Ciccocioppo R, Froidi R, Massi M. *Hypericum perforatum* CO₂ extract and opioid receptor antagonists act synergistically to reduce ethanol intake in alcohol-preferring rats. *Alcohol Clin Exp Res* 2003, 27:1554-1562
- Peron AP, Mariucci RG, de Almeida IV, Düsman E, Mantovani MS, Vicentini VE. Evaluation of the cytotoxicity, mutagenicity and antimutagenicity of a natural antidepressant, *Hypericum perforatum* L. (St. John's wort), on vegetal and animal test systems. *BMC Complement Altern Med* 2013, 13:97
- Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St. John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. *Br J Clin Pharmacol* 2003, 56:683-690
- Pharm. Eur.: European Pharmacopoeia, current edition.
- Pharm. Helv. 8: Swiss Pharmacopoeia. Eidgenössisches Department des Inneren, Bern 2001
- Philipp M, Kohnen R, Hiller KO. *Hypericum* extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. *BMJ* 1999, 319:1534-1538
- Piccolo P, Gentile S, Alegiani F, Angelico M. Severe drug induced acute hepatitis associated with use of St John's wort (*Hypericum perforatum*) during treatment with pegylated interferon α . *BMJ Case Rep* 2009, 2009. pii: bcr08.2008.0761

- Pilepić KH, Males Z, Crkvencić M. Quantitative analysis of total flavonoids and total phenolic acids in thirty *Hypericum* taxa. *Nat Prod Commun* 2013, 8(3):347-349
- Pirbalouti AG, Fatahi-Vanani M, Craker L, Shirmardi H. Chemical composition and bioactivity of essential oils of *Hypericum helianthemoides*, *Hypericum perforatum* and *Hypericum scabrum*. *Pharm Biol* 2014, 52(2):175-181
- Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. *Lancet* 2000, 355:547-548
- Popper CW. Mood disorders in youth: exercise, light therapy, and pharmacologic complementary and integrative approaches. *Child Adolesc Psychiatr Clin N Am* 2013, 22(3):403-441
- Portoles A, Terleira A, Calvo A, Martinez I, Resplandy G. Effects of *Hypericum perforatum* on ivabridine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. *J Clin Pharmacol* 2006, 46:1188-1194
- Prisăcaru AI, Andrițoiu CV, Andriescu C, Hăvârneanu EC, Popa M, Motoc AG, et al. Evaluation of the wound-healing effect of a novel *Hypericum perforatum* ointment in skin injury. *Rom J Morphol Embryol* 2013, 54(4):1053-1059
- Pu X, Liang J, et al. Therapeutic efficacy of *Hypericum perforatum* L. extract for mice infected with an influenza A virus. *Can J Physiol Pharmacol* 2012, 90:123-130
- Quandt J, Schmidt U, Schenk N. Ambulante Behandlung leichter und mittelschwerer depressiver Verstimmungen. *Der Allgemeinarzt* 1993, 2:97-102
- Radwan MA, Baky NA, Zaghloul I, Aboul-Enein HY. Pharmacokinetics and cardiovascular effect of etoricoxib in the absence or presence of St. John's Wort in rats. *Arzneimittelforschung* 2012, 62(7):313-318
- Raffa RB. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding. *Pharmacol Lett* 1998, 62:265-270
- Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. *Phytomed* 2006, 13:215-221
- Rapaport MH, Nierenberg AA, Howland R, Dording C, Schettler PJ, Mischoulon D. The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo. *J Psychiatr Res* 2011, 45(7):931-941
- Rašković A, Cvejić J, Stilinović N, Goločorbin-Kon S, Vukmirović S, Mimica-Dukić N, et al. Interaction between different extracts of *Hypericum perforatum* L. from Serbia and pentobarbital, diazepam and paracetamol. *Molecules* 2014, 19(4):3869-3882
- Ravindran AV, Lam RW, Filteau MJ, Lespérance F, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. *J Affect Disord* 2009, 117(Suppl. 1):S54-64
- Rayburn WF, Christensen HD, Gonzalez CL. Effect of antenatal exposure to St. John's wort (*Hypericum*) on neurobehavior of developing mice. *Am J Obstet Gynecol* 2000, 183:1225-1231
- Rayburn WF, Gonzalez CL, Christensen HD, Stewart JD. Effect of prenatally administered *Hypericum* (St. John's wort) on growth and physical maturation of mouse offspring. *Am J Obstet Gynecol* 2001a, 184:191-195

- Rayburn WF, Gonzalez CL, Christensen HD, Harkins TL, Kupiec TC. Impact of Hypericum (St.-John's-wort) given prenatally on cognition of mice offspring. *Neurotoxicol Teratol* 2001b, 23:629-637
- Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, *et al.* Opposite effects of short-term and long-term St. John's wort intake on the voriconazole pharmacokinetics. *Clin Pharmacol Ther* 2005, 78:25-33
- Reuter J, Huyke C, Scheuvens H, Ploch M, Neumann K, Jakob T, *et al.* Skin tolerance of a new bath oil containing St. John's wort extract. *Skin Pharmacol Physiol* 2008, 21(6):306-311
- Rezvani AH, Overstreet DH, Yang Y, Clark E Jr. Attenuation of alcohol intake by extract of *Hypericum perforatum* (St. John's Wort) in two different strains of alcohol-preferring rats. *Alcohol* 1999, 34:699-705
- Richard AJ, Amini ZJ, Ribnicky DM, Stephens JM. St. John's Wort inhibits insulin signaling in murine and human adipocytes. *Biochim Biophys Acta* 2012, 1822(4):557-563
- Röder C, Schaefer M, Leucht S. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort. *Fortschr Neurol Psychiatr* 2004, 72:330-343
- Rommelspacher H, Siemanowitz B, Mannel M. Acute and chronic actions of dry methanolic extract of *Hypericum perforatum* and a hyperforin-rich extract on dopaminergic and serotonergic neurones in rat nucleus accumbens. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S119-S126
- Roscetti G, Franzese O, Comandini A, Bonmassar E. Cytotoxic activity of *Hypericum perforatum* L. on K562 erythroleukemic cells: differential effects between methanolic extract and hypericin. *Phytother Res* 2004, 18:66-72
- Rothley M, Schmid A, Thiele W, Schacht V, Plaumann D, Gartner M, *et al.* Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation *in vitro* and suppress tumor-induced lymphangiogenesis *in vivo*. *Int J Cancer* 2009, 125:34-42
- Rudolf GAE, Zeller K. Johanniskrautextrakt verbessert die Lebensqualität. Eine Anwendungsbeobachtung an 4337 depressiven Patienten über 12 Wochen. *MMW Fortschr.Med* 2004, 146:77-80
- Ruedeberg C, Wiesmann UN, Brattstroem A, Honegger UE. *Hypericum perforatum* L. (St John's wort) extract Ze 117 inhibits dopamine re-uptake in rat striatal brain slices. An implication for use in smoking cessation treatment? *Phytother Res* 2010, 24(2):249-251
- Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. *Lancet* 2000, 355:548-549
- Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, *et al.* Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. *Phytother Res* 2014, 28(5):643-655
- Rychlik R, Siedentop H, von den Driesch V, Kasper S. St. John's wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200 mg active ingredient daily. *Fortschr Med Orig* 2001, 119:119-128
- Ryoo JG, Chun SI, Lee YJ, Suh HS. The effects of St. John's wort on premenstrual syndrome in single women: a randomized double-blind, placebo-controlled study. *Clin Psychopharmacol Neurosci* 2010, 8:30-37

- Sacher J, Houle S, Parkes J, Rusjan P, Sagrati S, Wilson AA, *et al.* Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study. *J Psychiatry Neurosci* 2011, 36(6):375-382
- Saito YA, Rey E, Almazar-Elder AE, Harmsen WS, Zinsmeister AR, Locke GR, *et al.* A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. *Am J Gastroenterol* 2010, 105(1):170-177
- Salje K, Lederer K, Oswald S, Dazert E, Warzok R, Siegmund W. Effects of rifampicin, dexamethasone, st. John's wort and thyroxine on maternal and foetal expression of Abcb1 and organ distribution of talinolol in pregnant rats. *Basic Clin Pharmacol Toxicol* 2012, 111:99-105
- Samadi S, Khadivzadeh T, Emami A, Moosavi NS, Tafaghodi M, Behnam HR. The effect of *Hypericum perforatum* on the wound healing and scar of cesarean. *J Altern Complement Med* 2010, 16(1):113-117
- Sardella A, Lodi G, Demarosi F, Tarozzi M, Canegallo L, Carrassi A. *Hypericum perforatum* extract in burning mouth syndrome: a randomized placebo-controlled study. *J Oral Pathol Med* 2008, 37(7):395-401
- Sarris J, Fava M, Schweitzer I, Mischoulon D. St John's wort (*Hypericum perforatum*) versus sertraline and placebo in major depressive disorder: continuation data from a 26-week RCT. *Pharmacopsychiatry*. 2012, 45(7):275-278
- Sattler S, Schaefer U, Schneider W, Hoelzl J, Lehr CM. Binding, uptake, and transport of hypericin by Caco-2 cell monolayers. *J Pharm Sci* 1997, 86:1120-1126
- Savikin K, Dobric S, Tadic V, Zdunic G. Antiinflammatory activity of ethanol extracts of *Hypericum perforatum* L., *H. barbatum* Jacq., *H. hirsutum* L., *H. richeri* Vill. and *H. androsaemum* L. in rats. *Phytother Res* 2007, 21:176-180
- Schempp CM, Winghofer B, Langheinrich M, Schöpf E, Simon JC. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady-state administration of *Hypericum perforatum* extract (St. John's wort). *Skin Pharmacol Appl Skin Physiol* 1999, 12:299-304 (abstract only)
- Schempp CM, Ludtke R, Winghofer B, Simon JC. Effect of topical application of *Hypericum perforatum* extract (St. John's wort) on skin sensitivity to solar simulated radiation. *Photodermatol Photoimmunol Photomed* 2000a, 16:125-128
- Schempp CM, Winghofer B, Ludtke R, Simon-Haarhaus B, Schopf E, Simon JC. Topical application of St John's wort (*Hypericum perforatum* L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. *Br J Dermatol* 2000b, 142:979-984
- Schempp CM, Simon-Haarhaus B, Simon JC. Phototoxic and apoptosis-inducing capacity of pseudohypericin. *Planta Med* 2002, 68:171-173
- Schempp CM, Windeck T, Hezel S, Simon JC. Topical treatment of atopic dermatitis with St. John's wort cream--a randomized, placebo controlled, double blind half-side comparison. *Phytomed* 2003a, 10:31-37
- Schempp CM, Winghofer B, Muller K, Schulte-Monting J, Mannel M, Schopf E, *et al.* Effect of oral administration of *Hypericum perforatum* extract (St. John's Wort) on skin erythema and pigmentation induced by UVB, UVA, visible light and solar simulated radiation. *Phytother Res* 2003b, 17:141-146

- Schimmer O, Krüger A, Paulini H, Häfele E. An evaluation of 55 commercial plant extracts in the Ames Mutagenicity test. *Pharmazie* 1994, 49:448-451
- Schlich D, Braukmann F, Schenk N. Behandlung depressoiver Zustandsbilder mit Hypericum Doppelblindstudie mit einem pflanzlichen Antidepressivum. *Psycho* 1987, 13:440-447
- Schmidt AJ, Krieg JC, Hemmeter UM, Kircher T, Schulz E, Clement HW, *et al.* Impact of plant extracts tested in attention-deficit/hyperactivity disorder treatment on cell survival and energy metabolism in human neuroblastoma SH-SY5Y cells. *Phytother Res* 2010, 24(10):1549-1553
- Schmidt M, Butterweck V. The mechanism of action of St. John's wort: an update. *Wien Med Wochenschr* 2015, 165:229-235
- Schmidt U. Zur Therapie depressiver Verstimmungen. *Psycho* 1989, 15:665-671
- Schmidt, U. Reactions unaffected by antidepressant treatment with the Hypericum preparation LI 160. *Nervenheilkunde* 1991, 10:311-312
- Schmidt U, Harrer G, Kuhn U, Berger-Deinert W, Luther D. Interactions of Hypericum extract with alcohol. *Nervenheilkunde* 1993, 12:324-319
- Schmitt LA, Liu Y, Murphy PA, Petrich JW, Dixon PM, Birt DF. Reduction in hypericin- induced phototoxicity by *Hypericum perforatum* extracts and pure compounds. *J Photochem Photobiol B, Biol* 2006a, 85:118-130
- Schmitt LA, Liu Y, Murphy PA, Birt DF. Evaluation of the light-sensitive cytotoxicity of *Hypericum perforatum* extracts, fractions, and pure compounds. *J Agric Food Chem* 2006b, 54:2881-2890
- Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. *Int Clin Psychopharmacol* 2000, 15:61-68
- Schrader E, Meier B, Brattström A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. *Human Psychopharmacol* 1998, 13:163-169
- Schreiber S, Prox-Vagedes V, Eloff E, Brueggemann I, Gademann G, Galazky I, *et al.* Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report. *BMC Cancer* 2010, 10:520
- Schüle C, Baghai T, Ferrera A, Laakmann G. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S127-S133
- Schulte Haas J, Dischkain Stolz E, Heermann Betti A, Stein AC, Schripsema J, Lino von Poser G, *et al.* The anti-immobility effect of hyperoside in the forced swimming test in rats is mediated by the D2-like receptors activation. *Planta Med* 2011, 77:334-339
- Schulz HU, Schürer M, Bässler B, Weiser D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a Hypericum extract containing tablet in healthy male volunteers. *Arzneimittelforschung* 2005a, 55:561-568
- Schulz HU, Schürer M, Bässler B, Weiser D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a Hypericum extract containing tablet. *Arzneimittelforschung* 2005b, 55:15-22

- Schulz HU, Schürer M, Bässler D, Weiser D. Investigation of the effect on photosensitivity following multiple oral dosing of two different *Hypericum* extracts in healthy men. *Arzneimittelforschung* 2006a, 56:212-221 (abstract only)
- Schulz V. Keine Aufhebung der kontrazeptiven Wirkung zweier Ovulationshemmer durch Johanniskrautextrakt. *Z. Phytother* 2004, 25:301-302
- Schulz V. Safety of St. John's wort extract compared to synthetic antidepressants. *Phytomed* 2006b, 13:199-204
- Schwarz UI, Büschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. *Br J Clin Pharmacol* 2003, 55:112-113
- Schwarz UI, Hanso H, Oertel R, Miehle S, Kuhlisch E, Glaeser H, *et al.* Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. *Clin Pharmacol Ther* 2007, 81:669-678
- Sell TS, Belkacemi T, Flockerzi V, Beck A. Protonophore properties of hyperforin are essential for its pharmacological activity. *Sci Rep* 2014, 4:7500
- Ševčovičová A, Šemeláková M, Pišíková J, Loderer D, Imreová P, Gálová E, *et al.* DNA-protective activities of hyperforin and aristoforin. *Toxicol In Vitro* 2015, 29(3):631-637
- Sharpley AI, McGavin CL, Whale R, Cowen PJ. Antidepressant-like effect of *Hypericum perforatum* (ST John's wort) on the sleep polysomnogram. *Pharmacopsychiatry* 1998, 139:286-287
- Shelton RC, Keller MB, Gelenberg A, Dunner DL, Herschfeld R, Thase ME, *et al.* Effectiveness of St John's wort in major depression: a randomized controlled trial. *JAMA* 2001, 285:1978-1986
- Shibayama Y, Ikeda R, Motoya T, Yamada K. St. John's wort (*Hypericum perforatum*) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study. *Food Chem Toxicol* 2004, 42:995-1002
- Siepmann M, Kirch W, Krause S, Joraschky P, Muek-Weymann M. The effects of St. John's wort extract and amitriptyline on autonomic responses of blood vessels and sweat glands in healthy volunteers. *J Clin Psychopharmacol* 2004, 24:79-82
- Siepmann M, Krause S, Joraschky P, Muek-Weymann M, Kirch W. The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men. *Br J Pharmacol* 2002, 54:272-282
- Silva BA, Dias AC, Ferreres F, Malva JO, Oliveira CR. Neuroprotective effect of *H. perforatum* extracts on beta-amyloid-induced neurotoxicity. *Neurotox Res* 2004, 6:119-130
- Silva B, Oliveira PJ, Dias A, Malva JO. Quercetin, kaempferol and biapigenin from *Hypericum perforatum* are neuroprotective against excitotoxic insults. *Neurotox Res* 2008, 13(3-4):265-279
- Silva SM, Martinho A, Moreno I, Silvestre S, Breitenfeld Granadeiro L, Alves G, *et al.* Effects of *Hypericum perforatum* extract and its main bioactive compounds on the cytotoxicity and expression of CYP1A2 and CYP2D6 in hepatoc cells. *Life Sci* 2016, 144:30-36
- Simbrey K, Winterhoff H, Butterweck V. Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex. *Life Sci* 2004, 74:1027-1038
- Simeon J, Nixon MK, Milin R, Jovanovic R, Walker S. Open-label pilot study of St. John's wort in adolescent depression. *J Child Adolesc Psychopharmacol* 2005, 15:293-301

- Simmen U, Schweitzer C, Burkard W, Schaffner W, Lundstrom K. *Hypericum perforatum* inhibits the binding of μ - and κ -opioid receptor expressed with the Semliki Forest virus system. *Pharm Acta Helv* 1998, 73:53-56
- Singer A, Schmidt M, Hauke W. Vergleich der Relapse- und Rezidivraten nach der Behandlung der mittelschweren Depression mit dem Johanniskrautextrakt STW 3-VI und Citalopram. *Nervenarzt* 2008, Suppl. 4:230
- Singer A, Schmidt M, Hauke W, Stade K. Duration of response after treatment of mild to moderate depression with *Hypericum* extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. *Phytomed* 2011, 18(8-9):739-742
- Singer A, Wonnemann M, Müller WE. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na^+ . *J Pharmacol Exp Ther* 1999, 290:1363-1368
- Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. Induction of imatinib metabolism by *hypericum perforatum*. *Blood* 2004, 104:1229-1230
- Smith PS. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. *Pharmacother* 2004, 24:1508-1514
- Sommer H, Harrer G. Placebo-controlled double-blind study examining the effectiveness of an *Hypericum* preparation in 105 mildly depressed patients. *J Geriatr Psychiatr Neurol* 1994, 7:S9-S11
- Sood A, Ebbert JO, Prasad K, Croghan IT, Bauer B, Schroeder DR. A randomized clinical trial of St. John's wort for smoking cessation. *J Altern Complement Med* 2010, 16(7):761-767
- Sosa S, Pace R, Bornancin A, Morazzoni P, Riva A, Tubaro A, et al. Topical anti-inflammatory activity of extracts and compounds from *Hypericum perforatum* L. *J Pharm Pharmacol* 2007, 59:703-709
- Staffeldt B, Kerb R, Brockmöller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the *hypericum perforatum* extract LI 160 in healthy volunteers. *J Geriatr Psychiatry Neurol* 1994, 7(Suppl. 1):S47-S53
- Stage TB, Pedersen RS, Damkier P, Christensen MMH, Feddersen S, Larsen JT, et al. Intake of St. John's wort improves the glucose tolerance in healthy subjects that ingest metformin compared to metformin alone. *Br J Clin Pharmacol* 2014, 79:298-306
- Stevinson C, Dixon M, Ernst E. *Hypericum* for fatigue – a pilot study. *Phytomed* 1998, 5:443-447
- Stevinson C, Ernst E. A pilot study of *Hypericum perforatum* for the treatment of premenstrual syndrome. *BJOG* 2000, 107:870-876
- Stevinson C, Ernst E. Can St. John's wort trigger psychoses? *Int J Clin Pharmacol Ther* 2004, 42:473-480 (abstract only)
- Subhan F, Khan N, Sewell RD. Adulterant profile of illicit street heroin and reduction of its precipitated physical dependence withdrawal syndrome by extracts of St John's wort (*Hypericum perforatum*). *Phytother Res* 2009, 23(4):564-571
- Sugimoto KI, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada KI, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. *Clin Pharmacol Ther* 2001, 70:518-524
- Süntar IP, Akkol EK, Yilmazer D, Baykal T, Kirmizibekmez H, Alper M, et al. Investigations on the *in vivo* wound healing potential of *Hypericum perforatum* L. *J Ethnopharmacol* 2010, 127(2):468-477

- Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with Hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. *BMJ* 2005, 330:503-506
- Tadros MG, Mohamed MR, Youssef AM, Sabry GM, Sabry NA, Khalifa AE. Involvement of serotonergic 5-HT_{1A/2A}, alpha-adrenergic and dopaminergic D₁ receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin. *Behav Brain Res* 2009a, 199(2):334-339
- Tadros MG, Mohamed MR, Youssef AM, Sabry GM, Sabry NA, Khalifa AE. Proapoptotic and prepulse inhibition (PPI) disrupting effects of *Hypericum perforatum* in rats. *J Ethnopharmacol* 2009b, 122:561-566
- Tanideh N, Namazi F, Andisheh Tadbir A, Ebrahimi H, Koohi-Hosseiniabadi O. Comparative assessment of the therapeutic effects of the topical and systemic forms of *Hypericum perforatum* extract on induced oral mucositis in golden hamsters. *Int J Oral Maxillofac Surg* 2014, 43(10):1286-1292
- Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. *Clin Pharmacol Ther* 2004, 75:298-309
- Tassone E, Maran C, Masola V, Bradaschia A, Garbisa S, Onisto M. Antidepressant hyperforin up-regulates VEGF in CNS tumour cells. *Pharmacol Res* 2011, 63:37-43
- Taylor LH, Kobak KA. An open-label trial of St. John's Wort (*Hypericum perforatum*) in obsessive-compulsive disorder. *J Clin Psychiatry* 2000, 61:575-578
- Teufel-Mayer R, Gleitz J. Effects of long-term administration of Hypericum extracts on the affinity and density of the central serotonergic 5-HT_{1A} and 5-HT_{2A} receptors. *Pharmacopsychiatry* 1997, 30(Suppl. 2):113-113
- Tian J, Zhang F, Cheng J, Guo S, Liu P, Wang H. Antidepressant-like activity of adhyperforin, a novel constituent of *Hypericum perforatum* L. *Sci Rep* 2014, 4:5632
- Tian JY, Tao RY, Zhang XL, Liu Q, He YB, Su YL, et al. Effect of *Hypericum perforatum* L. extract on insulin resistance and lipid metabolic disorder in high-fat-diet induced obese mice. *Phytother Res* 2015, 29(1):86-92
- Trana C, Toth G, Wijns W, Barbato E. St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial). *J Cardiovasc Transl Res* 2013, 6(3):411-414
- Traynor NJ, Beattie PE, Ibbotson SH, Moseley H, Ferguson J, Woods JA. Photogenotoxicity of hypericin in HaCaT keratinocytes: implications for St. John's Wort supplements and high dose UVA-1 therapy. *Toxicol Lett* 2005, 158:220-224
- Trofimiuk E, Braszko JJ. Alleviation by *Hypericum perforatum* of the stress-induced impairment of spatial working memory in rats. *Naunyn Schmiedebergs Arch Pharmacol* 2008, 376(6):463-471
- Trofimiuk E, Holownia A, Braszko JJ. Activation of CREB by St. John's wort may diminish deleterious effects of aging on spatial memory. *Arch Pharm Res* 2010, 33(3):469-477
- Trofimiuk E, Holownia A, Braszko JJ. St. John's wort may relieve negative effects of stress on spatial working memory by changing synaptic plasticity. *Naunyn Schmiedebergs Arch Pharmacol* 2011, 383(4):415-422
- Trofimiuk E, Walesiuk A, Braszko JJ. St John's wort (*Hypericum perforatum*) counteracts deleterious effects of the chronic restraint stress on recall in rats. *Acta Neurobiol Exp* 2006, 66:129-138

- Trofimiuk E, Walesiuk A, Braszko JJ. St John's wort (*Hypericum perforatum*) diminishes cognitive impairment caused by the chronic restraint stress in rats. *Pharmacol Res* 2005, 51:239-246
- Tugrul I, Demirci B, Demir O, Dost T, Birincioglu M. The effect of *Hypericum perforatum* on isolated rat aorta. *Pharm Biol* 2011, 49(8):879-883
- Turkanovic J, Ngo SN, Milne RW. Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver. *J Pharm Pharmacol* 2009, 61(8):1037-1042
- Uchida S, Hirai K, Hatanaka J, Hanato J, Umegaki K, Yamada S. Antinociceptive effects of St. John's wort, *Harpagophytum procumbens* extract and Grape seed proanthocyanidins extract in mice. *Biol Pharm Bull* 2008, 31(2):240-245
- Uebelhack R, Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo- controlled clinical trial. *Adv Ther* 2004, 21:265-275
- Uebelhack R, Blohmer JU, Graubaum H.J, Busch R, Gruenwald J, Wernecke KD. Black Cohosh and St. John's wort for climacteric complaints. *Obstet Gynecol* 2006, 107:247-255
- Uzday IT, Coskun I, Kayir H, Ozturk N, Ozturk Y. Extract of *Hypericum perforatum* blocks caffeine-induced locomotor activity in mice: a possible role of nitric oxide. *Phytother Res* 2007, 21:415-419
- Van Strater AC, Bogers JP. Interaction of St John's wort (*Hypericum perforatum*) with clozapine. *Int Clin Psychopharmacol* 2012, 27(2):121-124
- Vance KM, Ribnicky DM, Hermann GE, Rogers RC. St. John's Wort enhances the synaptic activity of the nucleus of the solitary tract. *Nutrition* 2014, 30(7-8 Suppl.):S37-42
- Vandenbogaerde AL, Cuveele JL, Proot P, Himpens BE, Merlevede WJ, de Witte PA. Differential cytotoxic effects induced after photosensitization by hypericin. *J Photochem Photobiol B* 1997, 38:136-142
- Verjee S, Brügger D, Abdel-Aziz H, Butterweck V. Permeation Characteristics of Hypericin across Caco-2 Monolayers in the Absence or Presence of Quercitrin - A Mass Balance Study. *Planta Med* 2015, 81:1111-1120
- Vieira ML, Hamada RY, Gonzaga NI, Bacchi AD, Barbieri M, Moreira EG, *et al.* Could maternal exposure to the antidepressants fluoxetine and St. John's Wort induce long-term reproductive effects on male rats? *Reprod Toxicol* 2013, 35:102-107
- Volz HP, Zeller K. Hochdosierter Johanniskrautextrakt als Einmalgabe: Ergebnisse einer Anwendungsbeobachtung an 11.296 Patienten. *Nervenheilkunde* 2000, 19:566-569
- Volz HP, Murck H, Kasper S, Moller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. *Psychopharmacol* 2002, 164:294-300
- Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. *Pharmacopsychiatry* 1997, 30(Suppl. 2):81-85
- Vorbach EU, Hübner WD, Arnoldt KH. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. *J Geriatr Psychiatry Neurol* 1994, 7(Suppl. 1):S19-S23
- Waksman JC, Heard K, Jolliff H, Daly FFS, Bogdan GM, Dart RC. Serotonin syndrome associated with the use of St. John's wort (*Hypericum perforatum*) and paroxetine. *Clin Toxicol* 2000, 38:521

- Wan H, Chen Y. Effects of antidepressive treatment of Saint John's wort extract related to autonomic nervous function in women with irritable bowel syndrome. *Int J Psychiatry Med* 2010, 40(1):45-56
- Wang Z, Gorski C, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St. John's wort (*Hypericum perforatum*) on human cytochrome P450 activity. *Clin Pharmacol Ther* 2001, 70:317-326
- Wang LS, Zhu B, El-Aty AMA, Zhou G, Li Z, Wu J, *et al.* The influence of St. John's wort on CYP2C19 activity with respect to genotype. *J Clin Pharmacol* 2004a, 44:577-581
- Wang LS, Zhou G, Zhu B, Wu J, Wang JG, El-Aty AMA, *et al.* St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. *Clin Pharmacol* 2004b, 75:191-197
- Wang XD, Li JL, Su QB, Guan S, Chen J, Du J, *et al.* Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. *Br J Clin Pharmacol* 2009, 67:255-261
- Wang Y, Shi X, Qi Z. Hypericin prolongs action potential duration in hippocampal neurons by acting on K⁺ channels. *Br J Pharmacol* 2010, 159(7):1402-1407
- Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. *Clin Pharmacol Ther* 2002, 71:414-420
- Weber W, Van der Stoep A, McCarty RL, Weiss NS, Biederman J, McClellan J. *Hypericum perforatum* (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents. *JAMA* 2008, 299:2633-2641
- Wenk M, Todesco L, Krahenbuhl S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. *Br J Clin Pharmacol* 2004, 57:495-499
- Werneke U, Horn O, Taylor DM. How effective is St John's wort? The evidence revisited. *J Clin Psychiatry* 2004, 65:611-617
- Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients--a controlled 6-week clinical trial. *Pharmacopsychiatry* 1997, 30(Suppl. 2):77-80
- Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. *Br J Clin Pharmacol* 2006, 62:512-526
- Wichtl, M. Teedrogen. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1984
- Wichtl, M. Teedrogen. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 2016
- Widy-Tyszkiewicz E, Piechal A, Joniec I, Blecharz-Klein K. Long term administration of *Hypericum perforatum* improves spatial learning and memory in the water maze. *Biol Pharm Bull* 2002, 25:1289-1294
- Wilhelm KP, Biel S, Siegers CP. Role of flavonoids in controlling the phototoxicity of *Hypericum perforatum* extracts. *Phytomed* 2001, 8:306-309
- Will-Shahab L, Bauer S, Kunter U, Roots I, Brattström A. St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. *Eur J Clin Pharmacol* 2009, 65(3):287-294
- Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. *BMJ* 2000, 321:536-539

- Wright CW, Gott M, Grayson B, Hanna M, Smith AG, Sunter A, *et al.* Correlation of hyperforin content of *Hypericum perforatum* (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study. *J Psychopharmacol* 2003, 17:403-408
- Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressmann J, *et al.* John's wort products according to hyperforin and total hypericin content. *J Am Pharm Ass* 2001a, 41:560-566
- Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressmann J, *et al.* Batch-to batch reproducibility of St. John's wort preparations. *Pharmacopsychiatry* 2001b, 34(Suppl. 1):S152-S156
- Wurglics M, Westerhoff K, Holoubek G, Schubert-Zsilavec M, Müller WE. Aktuelle Johanniskrautforschung. *Dtsch Apoth Ztg* 2002, 142:1153-1175
- Wurglics M, Schubert-Zsilavec M. Johanniskrautextrakt-Präparate im Vergleich. *Pharm Unserer Zeit* 2003, 32:236-241
- Wurglics M, Schubert-Zsilavec M. *Hypericum perforatum*: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. *Clin Pharmacokinet* 2006, 45:449-468
- Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, *et al.* CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations. *J Clin Pharmacol* 2005, 45:352-356
- Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. *Br J Pharmacol* 2008, 153(7):1579-1586
- Yang SY, Juang SH, Tsai SY, Chao PD, Hou YC. St. John's wort significantly increased the systemic exposure and toxicity of methotrexate in rats. *Toxicol Appl Pharmacol* 2012, 263(1):39-43
- Yildirim O, Canan F. A case of panic attack induced by St John's wort. *Prim Care Companion CNS Disord* 2013, 15:PCC. 1201453
- You MK, Rhuy J, Jeong KS, Bang MA, Kim MS, Kim HA. Effect of St. John's Wort (*Hypericum perforatum*) on obesity, lipid metabolism and uterine epithelial proliferation in ovariectomized rats. *Nutr Res Pract* 2014, 8(3):292-296
- Zaher M, Tang R, Bombarda I, Merhi F, Bauvois B, Billard C. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa. *Int J Oncol* 2012, 40(1):269-276
- Zahner C, Kruttschnitt E, Uricher J, Lissy M, Hirsch M, Nicolussi S, *et al.* No clinically relevant interactions of St. John's wort extract Ze 117 low in hyperforin with cytochrome P450 enzymes and p-glycoprotein. *Clin Pharmacol Ther* 2019, 106(2): 432-440
- Zdunic G, Godevac D, Milenkovic M, Vucicevic D, Savikin K, Menkovic N, *et al.* Evaluation of *Hypericum perforatum* oil extracts for an antiinflammatory and gatsoprotective activity in rats. *Phytother Res* 2009, 32:1559-1564
- Zhai XJ, Chen F, Chen C, Zhu CR, Lu YN. LC-MS/MS based studies on the anti-depressant effect of hypericin in the chronic unpredictable mild stress rat model. *J Ethnopharmacol* 2015, 169:363-369
- Zhou Y, Wang M, Yu L. An open study of St John's Wort extract in treatment of adolescent depression. *J Clin Psychosomatic Dis* 2009, 15 (Chinese. English translation of full text publication is enclosed).
- Zou Y, Lu Y, Wei D. Hypocholesterolemic effects of a flavonoid-rich extract of *Hypericum perforatum* L. in rats fed a cholesterol-rich diet. *J Agric Food Chem* 2005, 53:2462-2466

Zou YP, Lu YH, Wei DZ. Protective effects of a flavonoid-rich extract of *Hypericum perforatum* L. against hydrogen peroxide-induced apoptosis in PC12 cells. *Phytother Res* 2010, 24(Suppl. 1):S6-S10

References read but not included in assessment report

Abe A, Kaye AD, Gritsenko K, Urman RD, Kaye AM. Perioperative analgesia and the effects of dietary supplements. *Best Pract Res Clin Anaesthesiol* 2014, 28:183-189

Ables AZ, Baughman OL. Antidepressants: Update on new agents and indications. *Am.Fam.Physician* 2003, 67:547-554

Agostinis P, Vantiegghem A, Merlevede W, de Witte PAM. Hypericin in cancer treatment: more light on the way. *Int J Biochem Cell Biol* 2002, 34:221-241

Albrecht M, Hübner WD, Podzuweit H, Schmidt U. Johanniskraut-Extrakt zur Behandlung der Depression. Therapiebegleitende Anwendungsbeobachtung mit Jarsin-Dragees. *Kassenarzt* 1994, 41:45-54

Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb/food supplement – drug interactions: a systematic review. *Phytother Res* 2014, 28:1749-1755

Andreescu C, Mulsant BH, Emanuel JE. Complementary and alternative medicine in the treatment of bipolar disorder—a review of the evidence. *J Affect Disord* 2008, 110:16-26

Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. *JAMA* 2001, 286:208-216

Ara I, Bano S. St. John's Wort modulates brain regional serotonin metabolism in swim stressed rats. *Pak J Pharm Sci* 2009, 22:94-101

Araya OS, Ford EJ. An investigation of the type of photosensitization caused by the ingestion of St. John's wort (*Hypericum perforatum*) by calves. *J Comp Pathol* 1981, 91:135-141

Aronson JK. Clusiaceae – *Hypericum perforatum*. Meyler's side effects of herbal medicines. 2009, 95-99

Bagdonaite E, Janulis V, Ivanauskas L, Labokas J. Between species diversity of *Hypericum perforatum* and *H. maculatum* by the content of bioactive compounds. *Nat Prod Commun* 2012, 7:199-200

Bano S, Dawood S. Serotonergic mediation effects of St John's wort in rats subjected to swim stress. *Pak J Pharm Sci* 2008, 21:63-69

Bano S, Ara I, Saboohi K, Moattar T, Chaoudhry B. St. John's Wort increases brain serotonin synthesis by inhibiting hepatic tryptophan 2, 3 dioxygenase activity and its gene expression in stressed rats. *Pak J Pharm Sci* 2014, 27:1427-1435

Bano S, Gitay M, Ara I, Badawi A. Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels in rats. *Pak J Pharm Sci* 2010, 23: 266-272

Barnard DL, Huffman JH, Morris JL, Wood SG, Hughes BG, Sidwell RW. Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus. *Antiviral Res* 1992, 17:63-77

Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, et al. Amended safety assessment of *Hypericum perforatum*-derived ingredients as used in cosmetics. *Int J Toxicol* 2014, 33:5S-23S

- Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. *Pharmacother* 2000, 20:568-574
- Bennett DA Jr, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John's wort (*Hypericum*). *Ann Pharmacother* 1998, 32:1201-1208
- Bernd A, Simon S, Ramirez Bosca A, Kippenberger S, Diaz Alperi J, Miquel J, et al. Phototoxic effects of *Hypericum* extract in cultures of human keratinocytes compared with those of psoralen. *Photochem Photobiol* 1999, 69:218-221
- Bernhardt M, Liske E. Antidepressive Therapie mit Johanniskraut-Extrakt unter besonderer Berücksichtigung von zwei unterschiedlichen Dosierungsschemata. *Jatros Neurologie* 1996, 12:43-48
- Birt DF, Widrlechner MP, Hammer KDP, Hillwig ML et al. *Hypericum* in infection: Identification of anti-viral and anti-inflammatory constituents. *Pharm Biol* 2009, 47:774-782
- Bitran S, Farabaugh AH, Ameral VEA et al. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St. John's wort (*Hypericum perforatum*) versus a SSRI. *Int. Clin. Psychopharmacol* 2011, 26 :206-212
- Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V et al. The conduct of *in vitro* and *in vivo* drug-drug interaction studies: a PhRMA perspective. *J Clin Pharmacol* 2003, 43:443-469
- Booth JN III, McGwin G. The association between self-reported cataracts and St. John's wort. *Curr. Eye Res* 2009, 34:863-866
- Bouron A, Lorrain E. Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature. *Encephale* 2014, 40:108-113
- Bozin B, Kladar N, Grujic N et al. Impact of origin and biological source on chemical composition, anticholinesterase and antioxidant properties of some St. John's wort species (*Hypericum* spp. *Hypericaceae*) from the Central Balkans. *Molecules* 2013, 18:11733-11750
- Brattström A. Der Johanniskrautextrakt Ze 117. Wirksamkeit und Sicherheit. *Dtsch.Apoth.Ztg* 2002, 142:3695-3699
- Budzinski JW, Foster BC, Vandenhoeck S, Arnason JT. An *in vitro* evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. *Phytomed* 2000, 7:273-282
- Budzynska K, Gardner ZE, Dugoua JJ, Low Dog T, Gardiner P. Systematic review of breastfeeding and herbs. *Breastfeed Med* 2012, 7:489-503
- Bukhari IA, Dar A. Behavioral profile of *Hypericum perforatum* (St. John's Wort) extract. A comparison with standard antidepressants in animal models of depression. *Eur Rev Med Pharmacol Sci* 2013, 17(8):1082-1089
- Cai F, Li Y, Zhang M, Zhang H, Wang Y, Hu P. Combination of integrated expanded bed adsorption chromatography and countercurrent chromatography for the direct extraction and purification of pseudohypericin and hypericin from St. John's wort (*Hypericum perforatum* L.). *J Sep Sci* 2015, May 12
- Camfield DA, Sarris J, Berk M. Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. *Prog Neuropsychopharmacol Biol Psychiatry* 2011, 35:887-895

- Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. *Curr Drug Metab* 2011, 12(6):570-577
- Carpenter C, Crigger N, Kugler R, Loya A. Hypericum and nurses: a comprehensive literature review on the efficacy of St. John's Wort in the treatment of depression. *J Holist Nurs* 2008, 26:200-207
- Carpenter DJ. St. John's wort and S-adenosyl methionine as "natural" alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit? *Altern Med Rev* 2011, 16(1):17-39
- Carson SW, Hill-Zabala CE, Roberts SH, Hawke RL. Inhibitory effect of a methanolic solution of St. John's wort (*Hypericum perforatum*) on cytochrome P450 3A4 activity in human liver microsomes. *Clin Pharmacol Ther* 2000, 67:99
- Castro FC, Magre A, Cherpinski R, Zelante PM, Neves LM, Esquisatto MA, *et al.* Effects of microcurrent application alone or in combination with topical *Hypericum perforatum* L. and *Arnica montana* L. on surgically induced wound healing in Wistar rats. *Homeopathy* 2012, 101(3):147-153
- Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, *et al.* Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. *J Clin Psychiatry* 2011, 72(12):1669-1676
- Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJ, Cusin C, *et al.* Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. *Asian J Psychiatr* 2015, 13:23-29
- Chen XW, Sneed KB, Pan SY, Cao C, Kanwar JR, Chew H, *et al.* Herb-drug interactions and mechanistic and clinical considerations. *Curr Drug Metab* 2012, 13(5):640-651
- Chen XW, Serag ES, Sneed KB, Liang J, Chew H, Pan SY, *et al.* Clinical herbal interactions with conventional drugs: from molecules to maladies. *Curr Med Chem* 2011,18:4836-4859
- Choi YH, Chin YW, Kim YG. Herb-Drug interactions: focus on metabolic enzymes and transporters. *Arch Pharm Res* 2011, 34:1843-1863
- Cipriani A, Purgato M, Furukawa TA, Trespici C, Imperadore G, Signoretti A, *et al.* Citalopram versus other anti-depressive agents for depression. *Cochrane Database Syst Rev* 2012, 11;7:CD006534, in press, doi 10.1002/14651858.CD006534.pub2
- Colombo D., Lunardon L., Bellia G. Cyclosporine and herbal supplement interactions. *J Toxicol* 2014, article ID 145325
- Crockett SL, Poller B, Tabanca N, Pferschy-Wenzig EM, Kunert O, Wedge DE, *et al.* Bioactive xanthenes from the roots of *Hypericum perforatum* (common St John's wort). *J Sci Food Agric* 2011, 91(3):428-434
- Crockett SL, Robson NK. Taxonomy and Chemotaxonomy of the Genus *Hypericum*. *Med Aromat Plant Sci Biotechnol* 2011, 5(Special Issue 1):1-13
- Dante G, Bellei G, Neri I, Facchinetti F. Herbal therapies in pregnancy: what works? *Curr Opin Obstet Gynecol* 2014, 26(2):83-91
- Dante G, Pedrielli G, Annessi E, Facchinetti F. Herb remedies during pregnancy: a systematic review of controlled clinical trials. *J Matern Fetal Neonatal Med* 2013, 26(3):306-312

Dasgupta A, Hovanetz M, Olsen M, Wells A, Actor JK. Drug-herb interaction: effect of St. John's wort on bioavailability and metabolism of procainamide in mice. *Arch Pathol Lab Med* 2007, 131:1094-1098

Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. *Ther Drug Monit* 2008, 30(2):212-217

Datne G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. *J Psychosom Obstet Gyneol* 2011, 32:42-51

Davis SA, Feldman SR, Taylor SL. Use of St. John's Wort in potentially dangerous combinations. *J Altern Complement Med* 2014, 20(7):578-579

Deligiannidis KM, Freeman MP. Complementary and alternative medicine therapies for perinatal depression. *Best Pract Res Clin Obstet Gynaecol* 2014, 28(1):85-95

Deligiannidis KM, Freeman MP. Complementary and alternative medicine for the treatment of depressive disorders in women. *Psychiatr Clin N Am* 2010, 33:441-463

Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. *Curr Pharm Des* 2008, 14(17):1723-1742

Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E. Effect of acute administration of hypericum perforatum-CO₂ extract on dopamine and serotonin release in the rat central nervous system. *Pharmacopsychiatry* 2000, 33:14-18

Dimpfel W, Schober F, Mannel M. Effects of a methanolic extract and a hyperforin-enriched CO₂ extract of St. John's wort (*Hypericum perforatum*) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG). *Pharmacopsychiatry* 1998, 31(Suppl. 1):30-35

Dimpfel W, Schombert L. Central action of hyperici herba cum flore extractum siccum in freely moving rats. *Eur J Med Res* 1997, 2:491-496

Dimpfel W, Todorova A, Vonderheid-Guth B. Pharmacodynamic properties of St. John's wort-A single blind neurophysiological study in healthy subjects comparing two commercial preparations. *Eur J Med Res* 1999, 4:303-312

Ebrahimie M, Bahmani M, Shirzad H, Rafieian-Kopaei M, Saki K.A. Review Study on the Effect of Iranian Herbal Medicines on Opioid Withdrawal Syndrome. *J Evid Based Complementary Altern Med* 2015, Mar 26

Eğilmez OK, Kökten N, Ekici AI, Kalcioğlu MT, Yesilada E, Tekin M. The effect of *Hypericum perforatum* L. (St. John's Wort) on prevention of myringosclerosis after myringotomy in a rat model. *Int J Pediatr Otorhinolaryngol* 2015, 79(7):1128-1134

Ekin S, Oto G, Yardim Y, Levent A, Ozgokce F, Kusman T. Protective effect of *Hypericum perforatum* L. on serum and hair trace elements in rats 7,12-dimethylbenz[a]anthracene-induced oxidative stress. *Environ Toxicol Pharmacol* 2012, 33(3):440-445

El-Bakly WM, Hasanin AH. *Hypericum Perforatum* Decreased Hippocampus TNF- α and Corticosterone Levels with No Effect on Kynurenine/Tryptophan Ratio in Bilateral Ovariectomized Rats. *Korean J Physiol Pharmacol* 2014, 18(3):233-239

Farag MA, Wessjohann LA. Metabolome classification of commercial *Hypericum perforatum* (St. John's Wort) preparations via UPLC-qTOF-MS and chemometrics. *Planta Med* 2012, 78(5):488-496

- Farahani MS, Bahramsoltani R, Farzaei MH, Abdollahi M, Rahimi R. Plant-derived natural medicines for the management of depression: an overview of mechanisms of action. *Rev Neurosci* 2015, 26(3):305-321
- Feucht C, Patel DR. Herbal medicines in pediatric neuropsychiatry. *Pediatr Clin North Am* 2011, 58(1):33-54
- Filipiak-Szok A, Kurzawa M, Szłyk E. Determination of toxic metals by ICP-MS in Asiatic and European medicinal plants and dietary supplements. *J Trace Elem Med Biol* 2015, 30:54-58
- Firenzuoli R, Goli L. Toxicity of *Hypericum perforatum*. *Forsch Komplementärmed* 1999, 6:271
- Foster BC, Vandenhoeck S, Hana J, Krantis A, Akhtar MH, Bryan M, et al. *In vitro* inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. *Phytomedicine* 2003, 10:334-342
- Franco P, Potenza I, Moretto F, Segantin M, Grosso M, Lombardo A, et al. *Hypericum perforatum* and neem oil for the management of acute skin toxicity in head and neck cancer patients undergoing radiation or chemo-radiation: a single-arm prospective observational study. *Radiat Oncol* 2014, 29:9-297
- Franklin M, Chi JD, Mannel M, Cowen PJ. Acute effects of LI 160 (extract of *Hypericum perforatum*, St. John's wort) and two of its constituents on neuroendocrine responses in the rat. *J Psychopharmacol* 2000, 14:360-363
- Franklin M, Reed A, Murck H. Sub-chronic treatment with an extract of *Hypericum perforatum* (St. John's wort) significantly reduces cortisol and corticosterone in the rat brain. *Eur Neuropsychopharmacol* 2004, 14:7-10
- Franklin M. Sub-chronic treatment effects of an extract of *Hypericum perforatum* (St. John's wort, LI 160) on neuroendocrine responses to the 5-T2A agonist, DOI in the rat. *Pharmacopsychiatry* 2003, 36:161-164
- Franklin M, Cowen PJ. Researching the antidepressant actions of *Hypericum perforatum* (St. John's wort) in animals and man. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S29-S37
- Franklin M, Chi J, McGavin C, Hockney R, Reed A, Campling G, et al. Neuroendocrine evidence for dopaminergic actions of *hypericum* extract (LI 160) in healthy volunteers. *Biol Psychiatry* 1999, 46:581-584
- Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. *J Clin Psychiatry* 2010, 71(6):669-681; Comment in *J Clin Psychiatry* 2010, 71(6):667-668
- Freeman MP. Complementary and alternative medicine for perinatal depression. *J Affect Disord* 2009, 112(1-3):1-10
- Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, et al. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. *Eur J Clin Pharmacol* 2013, 69(3):507-513
- Galeotti N, Maidecchi A, Mattoli L, Burico M, Ghelardini C. St. John's Wort seed and feverfew flower extracts relieve painful diabetic neuropathy in a rat model of diabetes. *Fitoterapia* 2014, 92:23-33
- Galeotti N, Vivoli E, Bilia AR, Bergonzi MC, Bartolini A, Ghelardini C. A prolonged protein kinase C-mediated, opioid-related antinociceptive effect of st John's Wort in mice. *J Pain* 2010, 11(2):149-159

- Gambarana C, Ghiglieri O, Giachetti D, Taddei I. The administration of an hydro-alcoholic extract of *Hypericum perforatum* prevents the introduction of learned helplessness in rats. *Phytomed* 1996, 3:264
- Gambarana C, Ghiglieri O, Tolu P, De Montis MG, Giachetti D, Bombardelli E, *et al.* Efficacy of an *Hypericum perforatum* (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats. *Neuropsychopharmacol* 1999, 21:247-257
- Gangemi S, Minciullo PL, Miroddi M, Chinou I, Calapai G, Schmidt RJ. Contact dermatitis as an adverse reaction to some topically used European herbal medicinal products - part 2: Echinacea purpurea-Lavandula angustifolia. *Contact Dermatitis* 2015, 72(4):193-205
- Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, *et al.* The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. *Br J Clin Pharmacol* 2012, 75(2):431-439
- Gastpar M. *Hypericum* extract WS ® 5570 for depression--an overview. *Int J Psychiatry Clin Pract* 2013, 17(Suppl. 1):1-7
- Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of *in vitro* and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. *Cancer Treat Rev* 2013, 39(7):773-783
- Gorman GS, Coward L, Darby A, Rasberry B. Effects of herbal supplements on the bioactivation of chemotherapeutic agents. *J Pharm Pharmacol* 2013, 65(7):1014-1025
- Griffith TN, Varela-Nallar L, Dinamarca MC, Inestrosa NC. Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy. *Curr Med Chem* 2010, 17(5):391-406
- Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. *Planta Med* 2012, 78(13):1490-1514
- Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, *et al.* Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. *Mol Nutr Food Res* 2008, 52(7):755-763
- Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. *Mol Nutr Food Res* 2008, 52(7):772-779
- Haas JS, Stolz ED, Betti AH, Stein AC, Schripsema J, Poser GL, *et al.* The anti-immobility effect of hyperoside on the forced swimming test in rats is mediated by the D2-like receptors activation. *Planta Med* 2011, 77(4):334-339
- Haefeli WE, Carls, A. Drug interactions with phytotherapeutics in oncology. *Expert Opin Drug Metab Toxicol* 2014, 10: 359-377
- Hammer KD, Birt DF. Evidence for contributions of interactions of constituents to the anti-inflammatory activity of *Hypericum perforatum*. *Crit Rev Food Sci Nutr* 2014, 54(6):781-789
- Haw C, Stubbs J. Patient information leaflets for antidepressants: are patients getting the information they need? *J Affect Disord* 2011, 128(1-2):165-170
- Hazell P. Depression in children and adolescents. *BMJ Clin Evid* 2011, 21:1008
- Hazell P. Depression in children and adolescents. *BMJ Clin Evid* 2009, 7:1008

- Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. *Pharmacol Ther* 2000, 85:11-28
- Hoban CL, Byard RW, Musgrave IF. A comparison of patterns of spontaneous adverse drug reaction reporting with St. John's Wort and fluoxetine during the period 2000-2013. *Clin Exp Pharmacol Physiol* 2015, 42(7):747-751
- Hou Y, Aboukhatwa A, Lei DL, Manaye K, Khan I, Luo Y. Antidepressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. *Neuropharmacol* 2010, 58:911-920
- Howard C, Socratous E, Williams S, Graham E, Fowler MR, Scott NW, *et al.* PlantID - DNA-based identification of multiple medicinal plants in complex mixtures. *Chin Med* 2012, 28;7(1):18
- Hu ZP, Yang XX, Chen X, *et al.* A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. *Curr Drug Metab* 2007, 8:157-171
- Hussain S, Ansari ZH, Arif M. Hyperforin: a lead for antidepressants. *Int J Health Res* 2009, 2(1):15-22
- Iabichella ML. The use of an extract of *Hypericum perforatum* and *Azadirachta indica* in advanced diabetic foot: an unexpected outcome. *BMJ Case Rep* 2013, 13:2013. pii: bcr2012007299
- Isacchi B, Galeotti N, Bergonzi MC, Ghelardini C, Bilia AR, Vincieri FF. Pharmacological *in vivo* test to evaluate the bioavailability of some St John's wort innovative oral preparations. *Phytother Res* 2009, 23:197-205
- Jacobson I, Jönsson AK, Gerden B, Hägg S. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. *Pharmacoepidemiol Drug Saf* 2009, 18:1039-1047
- Jang SH, Kim DI, Choi MS. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. *BMC Complement Altern Med* 2014, 14:11
- Jat LR. Hyperforin: a potent anti-depressant natural drug. *Int J Pharm Pharm Sci* 2013, 5(S3):9-13
- Jeschke E, Ostermann T, Vollmar HC, Tabali M, Matthes H. Depression, Comorbidities, and Prescriptions of Antidepressants in a German Network of GPs and Specialists with Subspecialisation in Anthroposophic Medicine: A Longitudinal Observational Study. *Evid Based Complement Alternat Med* 2012, 2012:508623.
- Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. *Clin Pharmacokinet* 2011, 50(1):25-39
- Karyekar CS, Eddington ND, Dowling TC. Effect of St. John's wort extract on intestinal expression of cytochrome P4501A2 studies in LS180 cells. *J Postgraduate Med* 2002, 48: 97-100
- Kasper S. Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. *Wien Med Wochenschr* 2015, 165:217-228
- Kasper S, Caraci F, Forti B, Drago F, Aguglia E. Efficacy and tolerability of *Hypericum* extract for the treatment of mild to moderate depression. *Eur Neuropsychopharmacol* 2010, 20(11):747-765
- Kasper S, Gastpar M, Müller WE, Volz HP, Dienel A, Kieser M, *et al.* Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. *Eur Arch Psychiatry Clin Neurosci* 2008, 258(1):59-63

- Kelber O, Müller J, Okpanyi SN, Nieber K, Kolb C. From inflammation to depression – St. John's wort as a therapeutic approach. *Planta med* 2013, 79:13, 1259
- Khabbaz M. Effect of *Hypericum perforatum* aqueous extract on formalin induced pain and inflammation in mice. *Planta med* 2010, 76:1350
- Khan AU, Gilani AH. Antidiarrheal, antisecretory, and bronchodilatory activities of *Hypericum perforatum*. *Pharm Biol* 2009, 47:962-967
- Khan AU, Gilani AH. Natural Products Useful in Respiratory Disorders: Focus on Side-Effect Neutralizing Combinations. *Phytother Res* 2015, 29:1265-1285
- Kieser M, Szegedi A. Predicting stable treatment response in patients with major depression treated with *Hypericum* extract WS 5570/5572. *Pharmacopsychiatry* 2005, 38:194-200
- Kinrys G, Coleman E, Rothstein E. Natural remedies for anxiety disorders: potential use and clinical applications. *Depress Anxiety* 2009, 26(3):259-265
- Kıyan HT, Demirci B, Başer KH, Demirci F. The *in vivo* evaluation of anti-angiogenic effects of *Hypericum* essential oils using the chorioallantoic membrane assay. *Pharm Biol* 2014, 52(1):44-50
- Kleemann B, Loos B, Scriba TJ, Lang D, Davids LM. St John's Wort (*Hypericum perforatum* L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death. *PLoS One* 2014, 30;9(7):e103762
- Knüppel L, Linde K. Adverse effects of St. John's wort: a systematic review. *J Clin Psychiatry* 2004, 65:1470-1479
- Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John's wort drug interactions. *Curr Drug Metab* 2008, 9(10):1027-1037
- Kokalj M, Kolar J, Trafela T, Kreft S. Differences among *Epilobium* and *Hypericum* species revealed by four IR spectroscopy modes: transmission, KBr tablet, diffuse reflectance and ATR. *Phytochem Anal* 2011, 22(6):541-546
- Kresimon J, Rychlik R, Kiencke P, Kolb C, Kelber O, Müller J. Patienten mit mittelschwerer Depression unter Behandlung mit *Hypericum*-Extrakt STW3-VI (900 mg täglich) oder SSRI – prospektive 6-monatige Versorgungsstudie. *Z Phytother* 2012, 33(Suppl. 1):S22
- Krishtal O, Lozovaya N, Fisunov A, et al. Modulation of ion channels in rat neurons by the constituents of *Hypericum perforatum*. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S74-S82
- Kumar A, Garg R, Prakash AK. Effect of St. John's Wort (*Hypericum perforatum*) treatment on restraint stress-induced behavioral and biochemical alteration in mice. *BMC Complement Altern Med* 2010, 10:18
- Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. *Nutr J* 2010, 9:42
- Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. *J Geriatr Psychiatr Neurol* 1999, 12:7-10
- Läuchli S, Hafner J, Wehrmann C, French LE, Hunziker T. Post-surgical scalp wounds with exposed bone treated with a plant-derived wound therapeutic. *J Wound Care* 2012, 21(5):228-233
- Läuchli S, Vannotti S, Hafner J, Hunziker T, French L. A plant-derived wound therapeutic for cost-effective treatment of post-surgical scalp wounds with exposed bone. *Forsch Komplementmed* 2014, 21(2):88-93

Lawaetz AJ, Schmidt B, Staerk D, Jaroszewski JW, Bro R. Application of rotated PCA models to facilitate interpretation of metabolite profiles: commercial preparations of St. John's Wort. *Planta Med* 2009, 75(3):271-279

Lee JY, Duke RK, Tran VH, Hook JM, Duke CC. Hyperforin and its analogues inhibit CYP3A4 enzyme activity. *Phytochem* 2006, 67:2550-2560

Lemachatti J, Leveque D, Beretz L, Bergerat JP. Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients. *Anticancer Res* 2009, 29: 4741-4744

Li Z, Qin C, Li D, Hou Y, Li S, Sun J. Molecularly imprinted polymer for specific extraction of hypericin from *Hypericum perforatum* L. herbal extract. *J Pharm Biomed Anal* 2014, 98:210-220

Linde K. St. John's wort for depression - development of a Cochrane review from 1993 to 2008. *Z Evid Fortbild Qual Gesundh.wesen* 2008, 102:487-492

Linde K. St. John's wort - an overview. *Forsch Komplementmed* 2009, 16(3):146-155

Linde K, Knüppel L. Large-scale observational studies of *hypericum* extracts in patients with depressive disorders - a systematic review. *Phytomed* 2005, 12:148-157

Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, *et al.* Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. *Ann Fam Med* 2015, 13(1):69-79

Linde K, Schumann I, Meissner K, Jamil S, Kriston L, Rücker G, *et al.* Treatment of depressive disorders in primary care--protocol of a multiple treatment systematic review of randomized controlled trials. *BMC Fam Pract* 2011, 15;12:127

Linden M, Wurzenhof K, Ploch M, Schaefer M. Self medication with St. John's wort in depressive disorders: an observational study in community pharmacies. *J Affect Disord* 2008, 107(1-3):205-210

Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, *et al.* Fluoxetine versus other types of pharmacotherapy for depression. *Cochrane Database Syst Rev* 2013, 17;7:CD004185

Mai I, Krüger H, Budde K, Johne A, Brockmüller J, Neumayer HH, *et al.* Hazardous pharmacokinetic interaction of Saint John's wort (*Hypericum perforatum*) with the immunosuppressant cyclosporin. *Int J Clin Pharmacol Ther* 2000, 38:500-502

Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. *Drug Saf* 2004, 27:773-797

Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's wort (*Hypericum perforatum*) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. *Life Sci* 2000, 66: L133-L139

Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, *et al.* Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. *JAMA* 2003, 290:1500-1504

Matei AO, Gatea F, Radu GL. Analysis of Phenolic Compounds in Some Medicinal Herbs by LC-MS. *J Chromatogr Sci* 2015, 53(7):1147-1154

Menichini G, Alfano C, Marrelli M, Toniolo C, Provenzano E, Statti GA, *et al.* *Hypericum perforatum* L. subsp. *perforatum* induces inhibition of free radicals and enhanced phototoxicity in human melanoma cells under ultraviolet light. *Cell Prolif* 2013, 46(2):193-202

Milić N, Milosević N, Golocorbin Kon S, Bozić T, Abenavoli L, Borrelli F. Warfarin interactions with medicinal herbs. *Nat Prod Commun* 2014, 9(8):1211-1216

- Misane I, Ogren SO. Effects of *Hypericum perforatum* (St. John's wort) on passive avoidance in the rat: evaluation of potential neurochemical mechanisms underlying its antidepressant activity. *Pharmacopsychiatry* 2001, 34(Suppl. 1):89-97
- Mischoulon D. Update and critique of natural remedies as antidepressant treatments. *Obstet Gynecol Clin North Am* 2009, 36:789-807
- Mohammadi R, Amini K, Charehsaz S. Homeopathic treatment for peripheral nerve regeneration: an experimental study in a rat sciatic nerve transection model. *Homeopathy* 2012, 101(3):141-146
- Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, *et al.* St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. *Proc Natl Acad Sci USA* 2000, 97:7500-7502
- Mrozikiewicz PM, Bogacz A, Bartkowiak-Wieczorek J, Kujawski R, Mikolajczak PL, *et al.* Screening for impact of popular herbs improving mental abilities on the transcriptional level of brain transporters. *Acta Pharm* 2014, 64(2):223-232
- Müller J, Kolb C, Kelber O, Weiser D. High-dose St. John's wort extract STW 3-VI as a daily single-dose is safe and effective in the treatment of mild to moderate depression in different age-groups – results of a re-evaluation. *Planta med* 2010, 76:1357-1358
- Müller WE, Singer A, Wonnemann M. Hyperforin - Antidepressant activity by a novel mechanism of action. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S98-S102
- Murakami Y, Tanaka T, Murakami H, Tsujimoto M, Ohtani H, Sawada Y. Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. *Br J Clin Pharmacol* 2006, 61:671-676
- Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular). *J Nat Prod* 2010, 73(5):1015-1021
- Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, *et al.* Milnacipran versus other antidepressive agents for depression. *Cochrane Database Syst Rev* 2009, 8;(3):CD006529, in press, doi:10.1002/14651858.CD006529.pub2
- Nazıroğlu M, Çiğ B, Özgül C. Modulation of oxidative stress and Ca(2+) mobilization through TRPM2 channels in rat dorsal root ganglion neuron by *Hypericum perforatum*. *Neuroscience* 2014, 263:27-35
- Neary JT, Whitemore SR, Bu Y, Mehta H, Shi YF. Biochemical mechanisms of action of *Hypericum* LI 160 in glial and neuronal cells: inhibition of neurotransmitter uptake and stimulation of extracellular signal regulated protein kinase. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S103-S107
- Nieuwstraten C, Labiris NR, Holbrook A. Systematic overview of drug interactions with antidepressant medications. *Can J Psychiatry* 2006, 51:300-316
- Noeldner M, Chatterjee S. Effects of two different extracts of St. John's wort and some of their constituents on cytochrome P450 activities in rat liver microsomes. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S108-S110
- Nowack R. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's wort – and beyond! *Nephrol* 2008, 13:337-347
- Nowack R, Balle C, Birnkammer F, Koch W, Sessler R, Birck R. Impact of food and herbal medication on calcineurin inhibitor dose in renal transplant patients: a cross-sectional study. *J Med Food* 2011, 14:756-760

- Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from *in vivo* information. *Clin Pharmacokinet* 2008, 47(10):669-680
- Orčić DZ, Mimica-Dukić NM, Francišković MM, Petrović SS, Jovin ED. Antioxidant activity relationship of phenolic compounds in *Hypericum perforatum* L. *Chem Cent J* 2011, 25(5):34
- Pakseresht S, Boustani H, Azemi ME, Nilsaz J, Babapour R, Haghdust MR. Evaluation of Pharmaceutical Products of St. John's Wort Efficacy Added on Tricyclic Antidepressants in treating Major Depressive Disorder: A Double Blind Randomized Control Trial. *Jundishapur J Nat Pharm Prod* 2012, 7(3):106-110
- Panocka I, Perfumi M, Angeletti S, Ciccocioppo R, Massi M. Effects of *Hypericum perforatum* extract on ethanol intake, and on behavioral despair: a search for the neurochemical systems involved. *Pharmacol Biochem Behav* 2000, 66:105-111
- Peebles KA, Baker RK, Kurz EU, Schneider BJ, Kroll DJ. Catalytic inhibition of human DNA topoisomerase I α by hypericin, a naphthodianthrone from St. John's wort (*Hypericum perforatum*). *Biochem Pharmacol* 2001, 62:1059-1070
- Pennington K, Föcking M, McManus CA, Pariante CM, Dunn MJ, Cotter DR. A proteomic investigation of similarities between conventional and herbal antidepressant treatments. *J Psychopharmacol* 2009, 23(5):520-530
- Pirotta M, Densley K, Forsdike K, Carter M, Gunn J. St John's wort use in Australian general practice patients with depressive symptoms: their characteristics and use of other health services. *BMC Complement Altern Med* 2014, 14:204
- Pirotta M, Willis K, Carter M, Forsdike K, Newton D, Gunn J. 'Less like a drug than a drug': the use of St John's wort among people who self-identify as having depression and/or anxiety symptoms. *Complement Ther Med* 2014, 22(5):870-876
- Politi M, Zloh M, Pintado ME, Castro PM, Heinrich M, Prieto JM. Direct metabolic fingerprinting of commercial herbal tinctures by nuclear magnetic resonance spectroscopy and mass spectrometry. *Phytochem Anal* 2009, 20(4):328-334
- Popper CW. Mood disorders in youth: exercise, light therapy, and pharmacologic complementary and integrative approaches. *Child Adolesc Psychiatr Clin N Am* 2013, 22(3):403-441
- Posadzki P, Watson L, Ernst E. Herb-drug interactions: an overview of systematic reviews. *Br J Clin Pharmacol* 2013, 75(3):603-618
- Potter M, Moses A, Wozniak J. Alternative treatments in pediatric bipolar disorder. *Child Adolesc Psychiatr Clin N Am* 2009, 18(2):483-514
- Prakash DJ, Arulkumar S, Sabesan M. Effect of nanohypericum (*Hypericum perforatum* gold nanoparticles) treatment on restraint stress-induced behavioral and biochemical alterations in male albino mice. *Pharmacognosy Res* 2010, 2(6):330-334
- Putnik K, Stadler P, Schäfer C, Koelbl O. Enhanced radiation sensitivity and radiation recall dermatitis (RRD) after hypericin therapy – case report and review of literature. *Radiat Oncol* 2006, 1:32
- Rahimi R, Abdollahi M. An update on the ability of St. John's wort to affect the metabolism of other drugs. *Expert Opin Drug Metab Toxicol*. 2012, 8(6):691-708
- Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of *Hypericum perforatum* in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry* 2009, 33(1):118-127

- Rahman SZ, Basilakis J, Rahmadi A, Lujic S, Musgrave I, Jorm L, *et al.* Use of serotonergic antidepressants and St John's wort in older Australians: a population-based cohort study. *Australas Psychiatry* 2013, 21(3):262-266
- Ramos AA, Marques F, Fernandes-Ferreira M, Pereira-Wilson C. Water extracts of three *Hypericum* sps. Protect DNA from oxidative and alkylating damage and enhance DNA repair in colon cells. *Food Chem Toxicol* 2013, 51:80-86
- Rapkin AJ, Lewis EI. Treatment of premenstrual dysphoric disorder. *Womens Health (Lond Engl)* 2013, 9(6):537-556
- Reuter J, Merfort I, Schempp CM. Botanicals in dermatology: an evidence-based review. *Am J Clin Dermatol* 2010, 11(4):247-267
- Rigat M, Vallès J, D'Ambrosio U, Gras A, Iglésias J, Garnatje T. Plants with topical uses in the Ripollès district (Pyrenees, Catalonia, Iberian Peninsula): ethnobotanical survey and pharmacological validation in the literature. *J Ethnopharmacol* 2015, 164:162-179
- Rowe DJ, Baker AC. Perioperative risks and benefits of herbal supplements in aesthetic surgery. *Aesthet Surg J* 2009, 29(2):150-157
- Sánchez Gómez E, Arco Prados Y. Review of pharmacological interactions of oral anticancer drugs provided at pharmacy department. *Farm Hosp* 2014, 38(4):338-363
- Sanchez-Reus MI, Gomez del Rio MA, Iglesias I, Elorza M, Slowing K, Benedi J. Standardized *Hypericum perforatum* reduces oxidative stress and increases gene expression of antioxidant enzymes on rotenone-exposed rats. *Neuropharmacol* 2007, 52:606-616
- Santos-Filho SD, Bernard-Filho M. Evaluation of consequences of the treatment of blood with extracts of *Hypericum perforatum* and *menthe crispa*. *Med Chem Res* 2009, 18:545-554
- Sarris J. Clinical depression: an evidence-based integrative complementary medicine treatment model. *Altern Ther Health Med* 2011, 17(4):26-37
- Sarris J. St. John's wort for the treatment of psychiatric disorders. *Psychiatr Clin North Am* 2013, 36(1):65-72
- Sarris J, Camfield D, Berk M. Complementary medicine, self-shape, and lifestyle interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: a systematic review. *J Affective Disorders* 2011, 138:213-221
- Sarris J, Kavanagh DJ. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. *J Altern Complement Med* 2009, 15(8):827-836
- Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. *J Psychiatr Res* 2010, 44:32-41
- Sarris J, Kavanagh DJ, Deed G, Bone KM. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. *Hum Psychopharmacol* 2009, 24(1):41-48
- Sarris J, Kean J, Schweitzer I, Lake J. Complementary medicines (herbal and nutritional products) in the treatment of attention deficit hyperactivity disorder (ADHD): a systematic review of the evidence. *Compl Ther Med* 2011, 19:216-227
- Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. *CNS Drugs* 2013, 27(4):301-319

- Sarris J, Nierenberg AA, Schweitzer I, Alpert JE, Rosenbaum JF, Iovieno N, *et al.* Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's Wort in major depressive disorder. *J Clin Psychopharmacol* 2013, 33(6):827-830
- Sarris J, Panossian Am Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. *Eur Neuropsychopharmacol* 2011, 21:841-860
- Saxena A, Tripathi KP, Roy S, Khan F, Sharma A. Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. *Bioinformation* 2008, 3(5):198-204
- Schellenberg R, Sauer S, Dimpfel W. Pharmacodynamic effects of two different *hypericum* extracts in healthy volunteers measured by quantitative EEG. *Pharmacopsychiatry* 1998, 31(Suppl. 1):44-53
- Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, *et al.* Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. *Oncogene* 2002, 21:1242-1250
- Schempp CM, Pelz K, Wittmer A, Schopf E, Simon JC. Antibacterial activity of hyperforin from St. John's wort, against multiresistant *Staphylococcus aureus* and gram-positive bacteria. *Lancet* 1999, 353:2129
- Schey KL, Patat S, Chignell CF, Datillo M, Wang RH, Roberts JE. Photooxidation of lens alpha-crystallin by hypericin (active ingredient in St. John's Wort). *Photochem Photobiol* 2000, 72:200-203
- Schiavone BI, Rosato A, Marilena M, Gibbons S, Bombardelli E, Verotta L, *et al.* Biological evaluation of hyperforin and its hydrogenated analogue on bacterial growth and biofilm production. *J Nat Prod* 2013, 76(9):1819-1823
- Schmidt B, Jaroszewski JW, Bro R, Witt M, Staerk D. Combining PARAFAC analysis of HPLC-PDA profiles and structural characterization using HPLC-PDA-SPE-NMR-MS experiments: commercial preparations of St. John's Wort. *Anal Chem* 2008, 80(6):1978-1987
- Schneider, G. *Arzneidrogen*, Wissenschaftsverlag, Mannheim, 1990
- Schwarz D, Kisselev P, Schunck WH, Roots I. Inhibition of 17 β -estradiol activation by CYP1A1: genotype- and regioselective inhibition by St. John's Wort and several natural polyphenols. *Biochim Biophys Acta* 2011, 1814(1):168-174
- Seelinger G. Influence of *Hypericum* extract LI 160 on specific symptoms of depression in non-interventional studies with 20,000 patients. *Z Phytother* 2009, 30: 296-302
- Šemeláková M, Mikeš J, Jendželovský R, Fedoročko P. The pro-apoptotic and anti-invasive effects of hypericin-mediated photodynamic therapy are enhanced by hyperforin or aristoforin in HT-29 colon adenocarcinoma cells. *J Photochem Photobiol B* 2012, 117:115-125
- Shelton RC. St John's wort (*Hypericum perforatum*) in major depression. *J Clin Psychiatry* 2009, 70 (Suppl. 5):23-27
- Shi S, Klotz U. Drug interactions with herbal medicines. *Clin Pharmacokinet* 2012, 51:77-104
- Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. *Integr Cancer Ther* 2009, 8:208-227
- Silva BA, Oliveira PJ, Cristóvão A, Dias AC, Malva JO. Biapigenin modulates the activity of the adenine nucleotide translocator in isolated rat brain mitochondria. *Neurotox Res* 2010, 17(1):75-90

- Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K. Extracts and constituents of *Hypericum perforatum* inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. *J Recept Signal Transduct Res* 1999, 19:59-74
- Simmen U, Higelin J, Berger-Büter K, Schaffner W, Lundstrom K. Neurochemical studies with St. John's wort *in vitro*. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S137-S142
- Solomon D, Adams J, Graves N. Economic evaluation of St. John's wort (*Hypericum perforatum*) for the treatment of mild to moderate depression. *J Affect Disord* 2013, 148(2-3):228-234
- Sood A, Sood R, Brinker FJ, Mann R, Loehrer LL, Wahner-Roedler DL. Potential for interactions between dietary supplements and prescription medications. *Am J Med* 2008, 121:207-211
- Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. *Brain Inj* 2002, 16:359-367
- Tardivo JP, Wainwright M, Baptista MS. Local clinical phototreatment of herpes infection in São Paulo. *Photodiagnosis Photodyn Ther* 2012, 9(2):118-121
- Thiede HM, Walper A. Inhibition of MAO and COMT by *Hypericum* extracts and hypericin. *J Geriatr Psychiatry Neurol* 1994, 7(Suppl. 1):54-56
- Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. *Drug Metab. Dispos* 2005, 33:547-554
- Tian JY, Tao RY, Zhang XL, Liu Q, He YB, Su YL, *et al.* Effect of *Hypericum perforatum* L. extract on insulin resistance and lipid metabolid disorder in high-fat-diet induced obese mice. *Phytother Res* 2015, 29(1):86-92
- Toniolo C, Nicoletti M, Maggi F, Venditti A. HPTLC determination of chemical composition variability in raw materials used in botanicals. *Nat Prod Res* 2014, 28(2):119-126
- Trompetter I, Krick B, Weiss G. Herbal triplet in treatment of nervous agitation in children. *Wien Med Wochenschr* 2013, 163(3-4):52-57
- Tu P, Gibon J, Bouron A. The TRPC6 channel activator hyperforin induces the release of zinc and calcium from mitochondria. *J Neurochem* 2010, 112(1):204-213
- Uebelhack R, Franke L. *In vitro* effects of St. John's wort extract and hyperforin on 5 HT uptake and efflux in human blood platelets. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S146-S147
- Usai M, Leggio B, Grappi S, Nanni G, Gambarana C, Tolu P, *et al.* *Hypericum perforatum* subspecies angustifolium shows a protective activity on the consequences of unavoidable stress exposure at lower doses than *Hypericum perforatum*. *Pharmacopsychiatry* 2003, 36:283-287
- Uzbay TI. *Hypericum perforatum* and substance dependence: A review. *Phytother Res* 2008, 22:578-582
- Van Die MD, Bone KM, Burger HG, Reece JE, Teede HJ. Effects of a combination of *Hypericum perforatum* and *Vitex agnus-castus* on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. *J Altern Complement Med* 2009, 15(9):1045-1048
- Van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. *Hypericum perforatum* with *Vitex agnus-castus* in menopausal symptoms: a randomized, controlled trial. *Menopause* 2009, 16(1):156-163
- Van Gorp G, Meterissian GB, Haiek LN, McCusker J, Bellavance F. St John's wort or sertraline? Randomized controlled trial in primary care. *Can Fam Physician* 2002, 48:905-912

Vance KM, Ribnicky DM, Hermann GE, Rogers RC. St. John´s wort enhances the synaptic activity of the nucleus of the solitary tract. *Nutrition* 2014, 30:537-542

Vanoni C, Holsboer-Trachsler E. Wirksamkeit des Johanniskrautextraktes LI 160. Eine Anwendungsbeobachtung bei depressiven Patienten in der Allgemeinarztpraxis. *Ars medici* 2000, 5:277-280

Varteresian T, Lavretsky H. Natural products and supplements for geriatric depression and cognitive disorders: an evaluation of the research. *Curr Psychiatry Rep* 2014, 16:456-464

Velada I, Ragonezi C, Arnholdt-Schmitt B, Cardoso H. Reference genes selection and normalization of oxidative stress responsive genes upon different temperature stress conditions in *Hypericum perforatum* L. *PLoS One* 2014, 9(12): e115206

Vlachojanis J, Cameron M, Chrubasik S. Drug interactions with St. John's wort products. *Pharmacol Res* 2011, 63:254-256

Volz HP. Controlled clinical trials of *Hypericum* extracts in depressed patients - an overview. *Pharmacopsychiatry* 1997, 30(Suppl.):72-76

Volz HP, Laux P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. *Compr Psychiatry* 2000, 41(Suppl. 1):133-137

Wagner H, Bauer R. Arzneidrogen und ihre Inhaltsstoffe. Band 2. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1999

Wahlman J, Hirst M, Roberts JE, Prickett CD, Trevithick JR. Focal length variability and protein leakage as tools for measuring photooxidative damage to the lens. *Photochem Photobiol* 2003, 78:88-92

Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. *Int J Clin Pract* 2010, 64:835-838

Wang XD, Li JL, Chen X, Huang M, Chowbay B, Zhou SF. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: application to a clinical herb-drug interaction study. *J Chromatogr B* 2007, 852:534-544

Weber CC, Kressmann S, Fricker G, Müller WE. Modulation of P-glycoprotein function by St. John´s wort extract and its major constituents. *Pharmacopsychiatry* 2004, 37:292-298

Whittle N, Lubec G, Singewald N. Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice. *Amino Acids* 2009, 36:147-158

WHO monographs. WHO-Monographs on selected medical plants. World Health Organization, Geneva, 2002

Wichtl M. Herbal Drugs and Phytopharmaceuticals. Medpharm scientific publishers, Stuttgart 2004

Wielgus AR, Chignell CF, Miller DS, Van Houten B, Meyer J, Hu DN, et al. Phototoxicity in Human Retinal Epithelial Cells Promoted by Hypericin, a Component of St. John´s Wort. *Photochem Photobiol* 2006, 83:706-713

Will-Shahab L, Brattström A, Roots I, Bauer S, Kunter U, Labes D, et al. Studie zur Interaktion von Johanniskrautextrakt (Ze117) mit Kontrazeptiva an Probandinnen. Abstract Symposium 'Phytopharmaka VII', 15. 2001

Wölfle U, Seelinger G, Schempp CM. Topical application of St. John´s wort (*Hypericum perforatum*). *Planta Med* 2014, 80(2-3):109-120

- Wonnemann M, Singer A, Müller WE. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's wort: the role of amiloride sensitive sodium conductive pathways. *Neuropsychopharmacol* 2000, 23:188-197
- Wonnemann M, Singer A, Siebert B, Müller WE. Evaluation of the synaptosomal uptake inhibition of most relevant constituents of St. John's wort. *Pharmacopsychiatry* 2001, 34(Suppl. 1):S148-S151
- Xie HG, Kim RB. St John's wort-associated drug interactions: short-term inhibition and long-term induction? *Clin Pharmacol Ther* 2005, 78:19-24
- Zadayan G, Fuhr U. Phenotyping studies to assess the effects of phytopharmaceuticals on *in vivo* activity of main human cytochrome p450 enzymes. *Planta Med* 2012, 78(13):1428-1457
- Zhang H, Ying C, Tang Y. Anti-microbial screening of endophytic fungi from *Hypericum perforatum* Linn. *Pak J Pharm Sci* 2014, 27(5):1153-1156
- Zhao J, Liu W, Wang JC. Recent advances regarding constituents and bioactivities of plants from the genus *Hypericum*. *Chem Biodivers* 2015, 12(3):309-349
- Zhao X, Chen Q, Liu Y, Xia C, Shi J, Zheng M. Effect of xanthone derivatives on animal models of depression. *Curr Ther Res Clin Exp* 2014, 76:45-50
- Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. *J Psychopharmacol* 2004, 18:262-276
- Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. *Curr Drug Metab* 2008, 9(5):394-409
- Zörnig H. Arzneidrogen. Teil II. Verlag Klinkhardt, Leipzig, 1911
- Zou Y, Lu Y, Wei D. Antioxidant activity of a flavonoid-rich extract of *Hypericum perforatum* L. *in vitro*. *J Agric Food Chem* 2004, 52:5032-5039